Creating deletion strains to study the role of the argonaute and dicer genes in RNA interference in Cryptococcus neoformans by Curtis, Alan Dale & NC DOCKS at Western Carolina University
 
 
 
 
 
 
 
 
 
 
 
 
CREATING DELETION STRAINS TO STUDY THE ROLE OF THE ARGONAUTE 
AND DICER GENES IN RNA INTERFERENCE IN  
 CRYPTOCOCCUS NEOFORMANS  
 
 
A thesis presented to the faculty of the Graduate School of 
Western Carolina University in partial fulfillment of the  
Requirements for the degree of Master of Science in Biology. 
 
 
By 
 
 
Alan Dale Curtis, II 
 
 
Director: Dr. Indrani Bose 
Assistant Professor of Biology 
Biology Department 
 
Committee Members: Dr. Sean P. O’Connell, Biology 
Dr. Malcolm R. Powell, Biology 
 
July 2009 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
DEDICATION 
 
 
I dedicate this work to my family.  To my loving wife Traci and my beautiful daughter 
Addison: Thank you for serving as an inspiration for me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
 
 My utmost appreciation and sincere gratitude are due to a great multitude of 
individuals whose knowledge, kindness, and patience made this thesis a possibility.  I 
have not the space to personally thank everyone involved in this project, but I wish to 
thank a few particular individuals.   
My thesis advisor Dr. Indrani Bose was incredibly patient and provided me with 
guidance, encouragement, and the tools necessary for me to pursue a great many things.  
She provided me with lab space, instruments, and most importantly, knowledge - she 
taught me how to research molecular biology.  I also wish to thank my committee 
members, Drs. Sean O’Connell and Sabine Rundle.  Dr. O’Connell provided lab space 
when I had none, and additional materials that without, this project would never have 
come to completion, including the funding for the purified primers that led to my first 
successful overlap PCR.  Dr. Rundle provided lab materials, her sense of humor, and 
knowledge of the NFL and Monty Python during the preparation of this thesis, all of 
which I greatly appreciated (and needed).   
I would also like to thank Dr. Chris Coburn and Dr. Lori Seischab for critical 
reading of this thesis.  Their comments and guidance were of great help to me in the 
composition of such a work.  
Dr. Kathy Matthews allowed the use of her gradient thermal cycler and provided 
space in her ultra-low freezer, and for that, I am greatly thankful.  The entir faculty of 
iv 
 
the Biology Department at WCU proved to be of great help.  The discussions of my work 
with the faculty and other graduate students helped me learn, and I appreciate their 
interest in my project.  Dr. Greg Adkison allowed me to explain my work to him.  Once, 
sitting in the photo lab talking about gels, plasmids, and enzymes, he made me realize 
that I would do great.  I would also like to thank Dr. Malcolm Powell for standing behind 
Indi and me as we set up the lab from scratch and began work, as well as his willingness 
to sit on my committee with very little notice.  His patience and diligence are tho oughly 
appreciated.  
My gratitude is also given to Jenny Lodge for her GMC200 and pTEL-HYG 
plasmids that were used extensively in my thesis work. 
 I also wish to thank my high school biology teacher, Mr. George Radford 
Mayfield III.  Mr. Mayfield taught me biology and stimulated me to become interested in 
such a wonderful world of unknown molecular mechanisms.  Before I met him, I was 
undecided about a career goal, and now I have no regrets for dedicating my academic 
career to biology.  His classes served as the basis for my undergraduate career, which led 
to my graduate career, and ultimately, this thesis. 
Lastly, but certainly not least, I wish to express my deepest gratitude to my family 
for the constant moral and financial support required of a graduate student.  I wish to
thank my mom and dad, Sherri and Dale Curtis, as well as my grandparents, Jack and 
Violet Lutz, for their love and kindness.  Particularly, I thank my wife, Traci, who spent 
countless nights alone while I tirelessly worked toward the completion of this project.  
Thank you my darling, my love, for all that you do. 
 
 
v 
 
 
 
TABLE OF CONTENTS 
                
               Page 
List of Tables.....................................................................................................................vii 
List of Figures...................................................................................................................viii 
Abstract..............................................................................................................................10 
Introduction........................................................................................................................12 
 Serotypes................................................................................................................13 
 Mating System.......................................................................................................14 
 Infection.................................................................................................................15 
 Cryptococcus neoformans and Immunity..............................................................16 
 Virulence Factors...................................................................................................17 
 RNA Interference...................................................................................................19 
 Overlap PCR..........................................................................................................23 
Methods and Materials.......................................................................................................27 
 Determining Gene Regions For PCR.....................................................................27 
 Primer Design........................................................................................................28 
  AGO1 Knockout Primers...........................................................................28 
  AGO2 Knockout Primers...........................................................................29 
 Genomic DNA Extraction......................................................................................30 
 Overlap PCR Protocol............................................................................................31 
vi 
 
               Page 
 Overlap PCR Optimization....................................................................................34 
 Molecular Cloning Protocol...................................................................................34 
 Bacterial Cell Transformation................................................................................36 
 Colony PCR Protocol.............................................................................................36 
 Plasmid Preparation...............................................................................................37 
 Determining Restriction Sites For Plasmid Digestion...........................................37 
 Restriction Endonuclease Reactions......................................................................38 
 Plasmid Processing................................................................................................39 
 Ligation Protocol...................................................................................................39 
 Freezing Stocks of Plasmid-Containing Escherichia coli.....................................40 
Results................................................................................................................................41 
Discussion..........................................................................................................................83 
Future Work.......................................................................................................................88 
 Transformation of Cryptococcus via Biolistics to Produce Deletion Strains........88 
 Creating AGO1 and AGO2 Double Deletions.......................................................89 
 Screening Transformants for Gene Deletion.........................................................89 
 Creation of an AGO2 Complementation Construct...............................................90 
 Testing For the Presence of RNAi.........................................................................91
 Other Studies Involving ∆ago1 and ∆ago2 Mutants.............................................92 
References..........................................................................................................................93 
Appendices.........................................................................................................................99 
 
 
vii 
 
 
 
LIST OF TABLES 
 
 
 
Table                                                                                                                               Page  
 
1. AGO1, AGO2, DICER1 & DICER2 Gene Lengths and Loci.................................74   
2. AGO1 Knockout Primers........................................................................................75   
3. AGO2 Knockout Primers........................................................................................76  
4.  Primer Concentrations used in the first round of all OL-PCRs............................77 
5. Primer Concentrations used in the second (overlap) round of all OL-PCRs..........78 
6. AGO1 and AGO2 Colony PCR Primers..................................................................79   
7. Ligation Reaction Description................................................................................80   
8. G418 Complementation Primers.............................................................................81 
9. Complete Database of E. coli Stocks......................................................................82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
 
 
 
 
LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
1. The RNAi Pathway........................................................................................................49 
 
2a. Overlap PCR Amplification.........................................................................................50 
 
2b. Overlap PCR of Three Different PCR Products..........................................................51 
 
3. Graphic representation of pCR2.1 TOPO......................................................................52 
 
4. Graphic representation of pDrive...................................................................................53  
 
5. Creation of a Complementation Construct....................................................................54 
 
6a. Preliminary Amplicons of an OL-PCR........................................................................55 
 
6b. Overlap PCR of Amplicons from Figure 6a................................................................56 
 
7. Gradient PCR of the AGO2 Overlap..............................................................................57 
 
8. PCR of the AGO1, AGO2, DICER1 & DICER2 Genes in Their Entirety.....................58 
 
9. PCRs For Deletion Constructs.......................................................................................59 
 
10. Overlap PCR Deletion Constructs Using Fragments Shown in Figure 9....................60 
 
11. PCRs for Overlap Performed with AccuPrimeTM Pfx.................................................61 
 
12. Overlap PCR of AGO1 and AGO2 with AccuPrimeTM Pfx.........................................62 
 
13. Graphic Representation of the ago1 Deletion Construct.............................................63 
 
14. Separate AGO2::HYG Overlap PCRs..........................................................................64 
 
15. Purified Pooled AGO2::HYG OL-PCR.......................................................................65 
 
16. Graphic Representation of the ago2 Deletion Construct.............................................66 
 
 
ix 
 
 
 
17. Linearized TOPO-AGO1 and pDrive-DICER2 Plasmids............................................67 
 
18. TOPO-AGO1 Complementation Construct.................................................................68 
 
19. AGO1 Complementation Construct Colony PCRs......................................................69 
  
20. IBB103 Plasmid vs. TDB546 Plasmid PCRs..............................................................70  
 
21. Schematic of Forward and Reverse Orientations.........................................................71 
 
22. Orientation of AGO1(Neomycin) #1 and #2 Complementation Constructs................72   
 
23. The RNAi Plasmid.......................................................................................................73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
 
 
 
 
ABSTRACT 
 
 
 
CREATING DELETION STRAINS TO STUDY THE ROLE OF THE ARGONAUTE 
AND DICER GENES IN RNA INTERFERENCE IN CRYPTOCOCCUS 
NEOFORMANS 
 
Alan Dale Curtis, II, M.S. 
 
Western Carolina University, August 2009 
 
Director: Dr. Indrani Bose, PhD. 
 
 Cryptococcus neoformans is a spherical, encapsulated, basidiomycetous yeast and 
the causative agent of cryptococcosis, a form of meningitis that affects th  central 
nervous system of immunocompromised individuals (immunocompromised means 
patients with compromised immune systems).  Since the 1980’s and the emergence of the 
AIDS epidemic, much study has been concentrated on this fungus because cryptococcosis 
is 100% fatal in untreated patients.  Even with treatment, the condition does not always 
decrease in severity, and no major advancements in antifungal drugs have been made in a 
decade.  Recently, Cryptococcus has been shown to possess the necessary machinery for 
RNA interference (RNAi).  RNAi is a method of post-transcriptional gene silencing that 
may increase cryptococcal survival within mammalian hosts by controlling gene 
expression at various stages of the life cycle through heterochromatin and euchromatin 
rearrangement.  RNAi was first described in Caenorhabditis elegans in 1998 by Andrew 
Fire and his colleagues, and is best studied in Drosophila melanogaster.  The pathway 
includes argonaute and dicer proteins that aid in highly specific degradation of mRNA 
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in vivo.   To date, no organism has been shown to utilize RNAi as a factor for virulence, 
nor should it be thought of as such; however, this pathway may indeed play a role in the 
formation of certain virulence factors for C yptococcus, including the transcription of 
heat stress response genes required for thermotolerance, oxidative stress response genes 
such as those required for melanin and mannitol biosynthesis, as well as the formation of 
the polysaccharide capsule.  Two separate, yet equally effective methods were used in 
order to create deletion constructs of the AGO1 and AGO2 genes.  Overlap PCR and 
traditional cloning methods were employed.  While overlap PCR was optimized, 
molecular cloning techniques were also used to create the complementation constructs for 
the above genes.   
 Through overlap PCR, this study resulted in the creation of deletion constructs for 
the AGO1 and AGO2 genes, which are thought to play a role in RNAi.  This study also 
resulted in the creation of a complementation construct for the ago1 deletion.  These 
constructs can be biolistically inserted into C. neoformans to produce the corresponding 
deletion strains.  Once these strains are produced, future experiments will include many 
phenotypic studies between them and other known strains, as well as an eventual murine 
virulence study. 
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INTRODUCTION 
 
 
 
 Cryptococcus neoformans is a spherical, encapsulated, basidiomycetous yeast, 
and the causative agent of cryptococcosis (Buchannan & Murphy, 1998).  Until recently, 
two varieties of C. neoformans were recognized: C. neoformans var. neoformans and C. 
neoformans var. gattii (Mitchell & Perfect, 1995).  However, C. neoformans var. gattii is 
now considered a separate species (C. gattii), and a new variety, grubii has been assigned 
to C. neoformans, citing differences in phenotype, biochemistry, epidemiology, and other 
factors (Jaine & Fries, 2008).  The two species differ from each other in terms of capsule 
epitopes (serotype), biochemistry, epidemiology as well as geographical distribut on and 
habitat preference (Mitchell & Perfect, 1995; Jaine & Fries, 2008).  This cosmopolitan 
fungus is widespread throughout the geography of the planet, with C. neoformans found 
worldwide, and C. gattii emergent in tropical and sub-tropical environments.  
Cryptococcus gattii is often found in river forest gums (Eucalyptus 
camaldulensis) and forest red gums (Eucalyptus tereticornis) (Casadevall & Perfect, 
1998).  Cryptococcus neoformans was first isolated from fermenting peach juice in 1894 
by Sanfelice.  No other environmental isolates were recorded until 1951 when Emmons 
described C. neoformans in soils containing avian guano (Emmons, 1951), although C. 
neoformans was found inside skin lesions prior to 1951 (Mitchell & Perfect, 1995).  In 
fact, C. neoformans is closely associated with soils containing avian excreta, more 
specifically, pigeon (Columba livia) guano, and soils which are near avian nesting sites. 
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However avian species are not at risk for a cryptococcal infection (Litvintsea et al., 
2005, Nielsen et al., 2007).  In addition to soil and pigeon waste, C. neoformans has also 
been isolated from the air and other unusual places like bat caves, cockroaches, rabbit 
housings, and even bagpipes.  Cryptococcus neoformans, like C. gattii, has also been 
associated with species of Eucalyptus trees.  Cryptococcus neoformans has also been 
isolated from soils in Africa, Asia, Europe, North and South America, the Caribbean, and 
the Pacific Islands (Casadevall & Perfect, 1998).  It is, therefore, global in distribution 
and quite ubiquitous in nature.   
Serotypes 
C. neoformans has a prominent capsule that surrounds the organism.  This 
structure can be seen quite clearly upon staining the cells with India ink (Maxson et al., 
2006), and serves as the primary diagnostic tool for central nervous system infections 
(Bindschadler & Bennet, 1968).  Capsules of different cryptococcal varieties diff r subtly 
in structure, and these differences can be identified by the discriminatory binding of 
antibodies to these different strains.  Based on the various antibody responses generated, 
C. neoformans strains have been divided into serotypes that correlate well to the species 
nomenclature.  There are five different serotypes: A, B, C, D, and AD hybrids.  
Cryptococcus neoformans var. neoformans can possess capsular serotypes D or the AD 
hybrid; while C. neoformans var. grubii is the sole possessor of serotype A (Jaine & 
Fries, 2008).  Cryptococcus gattii may possess either serotype B or C.  They tend to 
infect immunocompetent hosts and usually carry a worse prognosis (Mitchell & Perfect, 
1995).  
14 
 
 
Of the five previously described serotypes, serotype A appears to be the most 
predominant, causing 99% of all cryptococcal infections in AIDS patients and greater 
than 80% in non-AIDS patients (Mitchell & Perfect, 1995).  Although C. gatti, which 
expresses serotypes B and C, are capable of pathogenesis within hosts with a competent 
immune system, infection is infrequent due to their limited geography, and thus only 
affect small populations in Africa and Australia (Litvintseva & Thakur, 2005).  Serotype 
A is more virulent and more common than Serotype D (Cherniak et al., 1980, Jaine & 
Fries, 2008). 
Mating System 
 Cryptococcus neoformans is considered bipolar, meaning that the organism exists 
sexually as two mating types – mating type a (MAT a) and mating type α (MAT α).  The 
MAT locus of the genome governs the sexual cycle of yeast and yeast-like fungi by 
establishing cell-type identity, and differs in DNA sequence between cells of opposite 
mating type.  In C. neoformans, for sexual reproduction to be successful, mating cells 
must possess the opposite allele (i.e., α with a); although recent work by Joseph Heitman 
et al. has shown that upregulation of the CPR2 gene may allow for α/α matings.  This 
may explain the Vancouver Island breakout in the late 1990’s (Hsueh, Xue, and Heitman, 
2009) where C. gattii infections rose to as much as 20 per million per year, twice the 
normal rate.  Some fungi are capable of switching mating types (homothallic); however, 
C. neoformans is heterothallic, meaning no mating type switching occurs.  The MAT 
locus is not only involved in mating type identification, but has also been linked to 
virulence.  Cryptococcus neoformans MAT α is more prevalent in both environmental and 
15 
 
 
clinical settings and is more virulent than MAT a types, in some serotypes (Fraser & 
Heitman, 2003; Neilsen, Marra, et al., 2005).  
Infection  
Cryptococcus neoformans is one of the few fungi that are capable of causing 
disease in immunocompromised mammalian hosts.  Patients with T-cell deficiencies are 
especially at risk of contracting a cryptococcal infection (Buchanan & Murphy, 1998).  
Patients with HIV/end-term AIDS, cancer patients who are receiving aggressive radiation 
therapy or chemotherapy as treatment, as well as transplant patients who are presc ibed 
post-transplant immunosuppressant steroids and individuals with congenital immune 
system defects are at a higher risk for cryptococcal infections (Waterm n et al., 2007).  
Cryptococcus enters the body through the lungs where it can establish a primary infection 
(Blanco & Garcia, 2008).  If the primary pulmonary infection is not held in check by the 
host immune system, the infection may spread to other organs and organ systems, 
especially the brain and the central nervous system.  Cryptococcus neoformans infects 
several organ systems of mammalian hosts, including the central nervous, cardiac, and 
respiratory systems.  Brain infections lead to cryptococcal meningitis, or cryptococcosis 
(Traynor & Huffnagle, 2001; Aguirre et al., 2004; Chen et al., 2007).  Heart disease can 
also be associated with C. neoformans.  Meningoencephalitis has a grimmer prognosis 
and is associated more closely with HIV/AIDS patients, whereas cryptococcal pneumonia 
is more often found in transplant patients and cancer patients (Buchanan & Murphy, 
1998).  
 If untreated, cryptococcal meningoencephalitis is 100% fatal, and cryptococcal 
infections are seemingly non-responsive to even the most effective antifungal dru s if the 
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host lacks an adequate T-cell-mediated immune response.  Cell-mediated immunity is 
essential for recovery in healthy individuals (Mitchell & Perfect, 1995).  Current FDA 
approved antifungals such as caspofungin are ineffective against a cryptococcal infe tion.  
These echinocandins target the cell wall of the fungus and are the only developments in 
antifungal drugs in the last decade (Odds, Brown, & Gow, 2003).  Thus, there is a dire 
need for novel antifungals that can be used as treatment options for cryptococcosis.  The 
HIV/AIDS pandemic, aggressive cancer treatments and an increase in organ transplant 
surgeries have fueled the increase in cryptococcosis cases world-wide (Mitchell & 
Perfect, 1995).  Because of this, and more importantly because the fungus has a high rate 
of mortality in immunocompromised patients, research on this organism has surged since 
the 1980’s. 
Cryptococcus neoformans and Immunity 
 Given the prevalence of C. neoformans, cryptococcosis is a relatively rare 
occurrence, suggesting that many more individuals come in contact with this organism 
than actually develop systemic disease.  Hosts with healthy cell-mediated immunity and a 
normal level of phagocytes have an effective defense against the fungus, and it has been 
shown that most healthy individuals possess antibodies to epitopes located on the cell 
wall of C. neoformans (Bindschadler & Bennett 1968; Keller et al., 1994).  Cryptococcus 
neoformans infects predominately via the lungs because normal innate barrier-type 
defenses (skin, mucous membranes) are successful in blocking the pathogen’s access to 
the interior.  Regarding defense, cell mediated immunity (CMI) can recognize the 
different serotypes of C. neoformans and is needed for an effective immune response for 
many mycoses (Blanco & Garcia, 2008).   
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Cell mediated immunity has two branches, TH-1 and TH-2.  The TH-1 branch of CMI 
is the mechanism responsible for clearance of a fungal pathogen such as C. neoformans. 
This is because TH-1 up-regulates interferon-gamma, increasing cellular immunity and 
phagocyte (macrophage) activation, whereas TH-2 up-regulates interleukins 3 and 4 (IL-3 
and IL-4), increasing antibody production (Blanco & Garcia, 2008; Traynor & Huffnagle, 
2004).  Macrophages and neutrophils are the two major types of phagocytic cells 
responsible for clearing a cryptococcal infection (Clemmons et al., 2000).  All of this 
relates to the pathogenicity of C. neoformans because CMI is dependent upon cluster 
differentiation 4 positive (CD4+) T-cells (Kwon-Chung et al., 2000; Aguirre et al., 2004).  
Once macrophages process C. neoformans, antigens are presented via MHC-II and CD4+ 
T-cell receptors recognize these antigen fragments, produce cytokines to recruit more 
macrophages, and proliferate, creating a full blown immune response (Kwon-Chung et 
al., 2000).  HIV/AIDS patients are susceptible to a cryptococcal infection due to a low 
CD4+ T-cell count that cripples the immune system resulting in great difficulty in clearing 
such an infection.  However, there are unique features of this fungus that allow it to cause 
systemic infection since most fungal infections are superficial. 
Virulence Factors 
 Virulence factors are simply any physiological or biochemical trait th t increases 
an organism’s ability to cause infection.  Cryptococcus neoformans has several different 
virulence factors.  The severity of disease developed by a given host is not only relia t on 
the organism’s virulence but also the state of the host’s immune response status (i.e., 
immunocompromised or immunosuppresed vs. immunocompetent).  Recognized 
virulence factors of C. neoformans include thermotolerance, melanin production, 
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mannitol synthesis, and the polysaccharide capsule (Buchanan & Murphy, 1998).  
Thermotolerance is perhaps the most simple virulence factor of any pathogen.  Without 
the ability to survive at body temperature (37ºC), . neoformans would be incapable of 
causing disease.  Calcineurin A is a catalytic subunit used as a stress response in yea t, 
and must be present in C. neoformans if the fungus is to survive, proliferate, and cause 
disease (Mitchell & Perfect, 1995).   
Melanin synthesis also plays a role in the ability of C. neoformans to cause 
disease.  Melanin production protects the fungus from oxidative reactions found within 
macrophages, allowing them to survive these types of environments.  However, C. 
neoformans is not capable of producing the precursors (i.e., dihydroxyphenols) of 
melanin, and must obtain these molecules from the environment.  The brain is rich in 
dihydroxyphenylalanine (DOPA), a type of dihydroxyphenol, and the fungus utilizes t to 
produce melanin (Buchanan & Murphy, 1998).     
Mannitol synthesis may also play a role in C. neoformans virulence.  The effects 
of mannitol are three-fold; mannitol may increase resistance to free oxygen radicals 
within the host (produced within macrophages via oxidative burst), as well as decreasing 
heat and osmotic stress (Buchanan & Murphy, 1998).   
High molecular weight polysaccharides on the surface of the capsule determin  
the serotype, and thus determine virulence, as some serotypes are more virulent than 
others.  Serotype A is more virulent than serotype D (Cherniak et al., 1980, Jaine & Fries, 
2008) and is only found in C. neoformans var. grubii, leaving serotypes D and the AD 
hybrid as the sole serotypes of C. neoformans var. neoformans (Jaine & Fries, 2008).  
Also, acapsular C. neoformans mutants have a greatly reduced degree of virulence in 
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relation to wild-type C. neoformans fungi with a functional capsule (Fromtling et al., 
1982).  Neutrophils, monocytes, and macrophages are more successful in killing 
acapsulated fungi, because the capsule protects the fungus from phagocytosis, thus 
decreasing antigen presentation to T-cells, and reducing the overall immune response 
(Buchanan & Murphy, 1998).  Also, wild type encapsulated C. neoformans does not 
stimulate the production of proinflammatory cytokines such as TNF-α, IL 1β, and IL-6 
as effectively as acapsular mutants (Levitz et al., 1994; Vecchiarelli et a ., 1995; Delfino 
et al., 1997).     
RNA Interference 
 Cryptococcus neoformans is capable of performing RNA interference (RNAi).  
RNAi is a well-studied method of post-transcriptional gene silencing (Dykxhoorn et al.,
2005) that was first observed in petunias, but could not be explained.   RNAi was 
formally described by Andrew Fire and his colleagues in Caenorhabditis elegans.  The 
molecular mechanism was determined using genetic studies of Drosophila melanogaster.  
In 1990, Carolyn Napoli and her colleagues were attempting to create an aesthetic vari ty 
of petunia that was dark purple in color (Napoli et al., 1990).  To do this, they created 
transgenic plants containing multiple copies of the chalcone synthase gene, an enzyme
required for the production of the purple pigment.  Upon inflorescence, the flowers were 
not dark purple; rather, they were white, or contained blotchy patterns of purple and 
white.  The reason for this phenomenon was unknown at the time, although it was 
hypothesized that some form of post-transcriptional gene silencing, termed ‘rev rsible 
co-suppression,’ was responsible.  One year later, Fire and his colleagues were 
attempting to abrogate gene expression in Caenorhabditis elegans via introducing ssRNA 
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into the nematode (Fire et al., 1991).  Later, they were attempting the same go l and used 
a racemic mixture of sense and anti-sense small interfering RNA (siRNA) as a control.  
Serendipitously, they found that introducing the sense and anti-sense mixture into C. 
elegans led to the specific degradation of homologous mRNA.  They propsosed that the 
sense and anti-sense strands hybridized n vivo and formed dsRNA which was acted on 
by some catalytic element that successfully silenced the genes. This sequenc -specific 
silencing of genes was evidence of a molecular mechanism they dubbed RNA 
interference, or RNAi (Fire, Xu, Montgomery, et al., 1998).   
 Initially, RNAi was thought to be unrelated to other post-transcriptional gene 
silencing mechanisms in plants and quelling in Neurospora.  However, all such 
mechanisms utilize dsRNAs that are homologous to the silenced gene (Dykxhoorn et al., 
2005).   Also, many proteins found in these post-transcriptional gene silencing pathways 
are highly conserved across the plant, fungi, and animal kingdoms (Fagard et al., 2000; 
Liu et al., 2003).  Since the revelation that RNAi occurs in mammalian cell cultures, 
researchers have attempted to understand the mechanisms behind RNAi and investigate 
any therapeutic use (Tuschl et al., 1999; Elbashir et al., 2001; Dykxhoorn et al., 2005) 
 Although the RNAi pathway is most well described in Drosophila melanogaster, 
the major effectors described below are also found in Cryptococcus neoformans.  Small 
interfering RNAs (siRNAs) direct mRNA degradation in vivo.  siRNAs are short (20-25 
nucleotides) double-stranded portions of RNA, which are produced from much longer 
dsRNA segments.  The dsRNA segments are digested by a family of RNase III-like 
proteins called dicers.  Dicer proteins are thought to be found in the cytoplasm, and act 
on dsRNA present in the cytoplasm.  dsRNA can be found in the cytoplasm for many 
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reasons, such as infection by a dsRNA virus, transposable elements, or some 
experimental dsRNA introduced by researchers.  Dicers digest long dsRNA in such a way 
that produces a dsRNA duplex (20-23 nucleotides in length), leaving an overhang of 2-3 
nucleotides on the 3’ end of each strand (Okamura et al., 2004).  Purified dicer can 
effectively digest long dsRNA into siRNAs in vitro.  In vivo, dicer forms a heterodimer 
with R2D2, a dsRNA binding protein, which studies suggest allows the siRNA to be 
incorporated into the RNA-Induced Silencing Complex (RISC) (Tomari et al., 2004; Liu 
et al., 2003).   
 Dicers, R2D2, and siRNAs are not the only effectors in this pathway.  The highly 
conserved family of argonaute (AGO) proteins is involved in development of organisms, 
stem cell fate determination, and the RNAi pathway (Carmel et al., 2002).  Argonaute 
proteins are an essential component to the multi-subunit RISC.  These proteins are highly 
basic in pH (Nagayashiki et al., 2005), making them a prime candidate for RNA binding, 
as argonaute proteins do bind ribohomopolymers in vitro (Kataoka et al., 2001).  
Argonaute proteins are RNase-H like enzymes that contain two highly conserved 
domains: the PAZ and PIWI domains.  The PAZ domain is thought to be responsible for 
binding the 2-3 nucleotide 3’-overhangs of siRNAs and thus anchor the siRNA to the 
argonaute protein (Huafang et al., 2004).  The PIWI (RNase-H fold) domain of the 
Argonaute protein is known to bind RNA, but has an affinity for the 5’ terminus (Yuan et 
al., 2005).  Argonaute proteins, then, are necessary for siRNA-directed mRNA cleavage.  
Grishok and his colleagues (Grishok et al., 2000) have shown that particular genes 
belonging to the argonaute family of proteins are required for RNAi in C. elegans, further 
suggesting that the argonaute proteins play a large role in the RNAi mechanism. Also, in 
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2004, Okamura and his colleagues discovered that ∆ago2 Drosophila, flies which lack 
AGO2, a gene that encodes an argonaute protein, do not show siRNA-directed RNAi.  
This study also determined that Argonaute proteins were, at least in Drosophila, required 
for the integration of siRNAs into the RISC and are in some way related to the unwinding 
of the siRNA duplex (Okamura et al., 2004).  Also in 2004, it was determined that 
Argonaute proteins are the catalytic elements of RNAi, serving as the endonuclease, also 
called a slicer, which loads the siRNA into the RISC and initiates target mRNA cleavage 
(Liu et al., 2004).  After long dsRNAs are processed by dicer into siRNAs and loaded 
into the RISC via Argonaute and R2D2, the RISC is targeted toward mRNA in the 
cytoplasm of the cell.  The siRNAs identify the mRNA via complementary base pairing, 
and the Argonaute protein cleaves the mRNA transcript at the 3’ end, preventing 
translation into protein (Figure 1). 
 To date, RNAi has not been shown as a requirement for virulence in any 
organism.  It has, however, been shown to affect the chromatin status of chromosomes in 
certain organisms, which could ultimately lead to altered gene expression, possibly 
leading to changes in expression of certain proteins required for virulence.  Beause C. 
neoformans possesses the needed machinery for RNAi, it may play a role in the 
formation of virulence factors that allow the fungus to infect a mammalian host. The first 
step in establishing the role of RNAi in C. neoformans virulence is to create gene 
deletions of the major players in the RNAi pathway.  
 In 2006, a study was performed by Hitoshi Nakayashiki and his colleagues with 
the purpose of screening fungi for genes with homology to Drosophila genes involved in 
RNAi (Nakayashiki et al., 2006).  This study found five gene regions within C. 
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neoformans that possess homology to RNAi genes in Drosophila and Arabidopsis.  Of 
the five genes identified by Nakayashiki, the current work focuses on four.  These include 
the argonaute (AGO1 and AGO2) genes and the dicer (DICER1 and DICER2) genes.  
Nakayashiki and his colleagues also determined the loci of these genes, allowing for 
retrieval.  Table 1 gives the descriptions of these loci, including gene size. 
The entire DNA sequence of the C. neoformans genome (with predicted proteins) 
is available on the web through The Institute for Genomic Research (TIGR) 
(www.tigr.org/tdb/fungal).   Chromosomal information and contigs are also available 
through the Saint Louis Bioinformatics Facility (genome.slu.edu).  Given these
sequences, it is feasible to locate these genes and create knock-out constructs by an 
overlap PCR method (described below), as well as create complementation constructs for 
the deletions using molecular cloning techniques. 
Overlap PCR  
The polymerase chain reaction (PCR) was developed by Kary Mullis in 1983.  
The eventual Nobel Prize winner in Chemistry (1993) is credited with the development of 
the PCR used in labs around the world today, although Klepp and his co-workers 
published a study concerning the replication of short DNA templates using primers and 
DNA polymerases in 1971.  This study received little attention however, paving the way 
for Dr. Mullis’ landmark development that changed the way molecular biology is 
performed by offering an all-purpose tool for many types of experiments.   
The basis of PCR is quite simple.  Temperature cycling facilitates the 
polymerization of DNA in vitro.  To begin with, the double stranded DNA must be 
separated into single strands of DNA (a process called melting or denaturation).  To do 
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this, the temperature is raised to approximately 94°C, where the hydrogen bonds between 
the double helix break, resulting in two single strands of DNA.  Once the DNA is 
“melted,” the temperature is lowered in order for primer binding to occur (a process 
called annealing).  The annealing temperature varies between primers, and allows for 
bonds to be formed between the single-stranded DNA and the single-stranded 
oligonucleotide primer.  The 3’ end of the primer offers a hydroxyl group, to which te 
DNA polymerase adds the next nucleotide in the sequence, ultimately resulting in a 
nascent DNA strand.  However, before the polymerase can polymerize the new DNA, the 
temperature must be raised to approximately 72°C (a process called 
extension/elongation), or the optimal temperature for the given enzyme’s function.  This 
also removes non-specific binding of primers to DNA sequences of low homology, 
adding stringency to the procedure.  The bases added are complementary to the template 
DNA strand, thus making a complete DNA double-helix with two strands.  The reaction 
progresses in this manner until the temperature is raised again to 94°C and DNA copy 
number is doubled after annealing and elongation. 
Since the mid 1980’s, PCR has been adapted for a myriad of molecular 
applications.  Using a heat-stable DNA polymerase such as the TAQ polymerase (from 
the bacterium Thermus aquaticus found in hot springs of Yellowstone National Park), 
synthesized oligonucleotide primers, deoxynucleotides, a buffer, magnesium chloride 
(TAQ polymerase cofactor), and a template strand of DNA, PCR can generate many 
copies of DNA from that template, allowing for subsequent enzymatic reactions, 
microarray, in vitro transcription, microinjection, or sequencing.   
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PCR has many modifications that allow it to serve many different purposes within
molecular biology, as well as other fields.  Researchers can utilize PCR to screen for 
clones using colony PCR. Viral RNA may be amplified using reverse –transcriptase PCR, 
allowing the viral genome to be sequenced for further genetic and evolutionary studies.  
Some versions of PCR vary the temperatures used in order to decrease background noise 
in the reaction.  Hospitals have also adapted PCR for use as a diagnostic tool for 
detecting certain diseases, such as an HIV infection, or certain well-studied diseases such 
as tuberculosis (Haldar, et al., 2009).  PCR has also been modified to allow for multiple 
fragments of DNA to be fused together in order to create constructs for gene deletion 
strains of organisms (Davidson et al., 2002), as well as constructs for making fusion 
proteins for use in immunological studies and drug targeting (Mannie et al., 2006).   This 
form of PCR, termed overlap PCR, has gained much popularity and was employed in 
this study to achieve gene deletion constructs. 
The overlap polymerase chain reaction (OL-PCR) is a PCR-based strategy for 
rapid gene deletion, and has been demonstrated as a high throughput mechanism for 
genetic analysis (Davidson et al., 2002).  OL-PCR was developed by Davidson et al. for 
use in Cryptococcus neoformans, and they used this molecular tool to disrupt several 
different genes in order to study their function.  The technique consists of two separate 
rounds of PCR, and has comparable efficacy to more traditional cloning techniques.  
However, OL-PCR is much faster, and is usually a cheaper option. 
During the first round of PCR, individual DNA fragments are amplified using 
primers that generate small overlapping regions between specific fragments.  This allows 
for fusion of all the fragments in the second round of PCR using primers to the outermost 
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sequences.  Overall, to delete chromosomal genes via OL-PCR, the sequences of the 
genes to be deleted must be known.  In order to successfully create deletion constructs 
using this method, the flanking regions of the gene must be amplified and fused with a 
selectable marker.  The marker is used to confirm the presence of the construct i  vivo, 
and the flanking regions are necessary for homologous recombination to occur.   
The purpose of this study was to create strains of Cryptococcus neoformans which 
lack the AGO1 and AGO2 genes, as well as the DICER1 and DICER2 genes from the 
genome so that further studies can use these strains to test for the functionality of RNAi 
and ultimately for virulence.  It was hypothesized that RNAi would cease to function 
within strains of C. neoformans which lack either both Argonaute or both Dicer genes, 
and that ultimately, the absence of RNAi would lead to decreased efficacy of virulence 
within these strains. 
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METHODS AND MATERIALS 
 
 
 
Determining Gene Regions For PCR 
 The entire genome of cryptococcal strain JEC21 serotype D with predicted 
proteins is available from the TIGR Fungal Database (www.tigr.org/tdb/fungal).  The loci 
for the four genes targeted for deletion in this study are published and readily available 
(Nakayashiki, et al., 2006) (Table 1).  Nakayashiki and his colleagues identified the 
AGO1 and AGO2 genes to be located at the CNJ00490 and CNJ00610 loci, respectively, 
and the DICER1 and DICER2 genes at the CNC03670 and CNC03680 loci, respectively. 
The AGO genes are on chromosome 10 of the cryptococcal genome, whereas the DICER 
genes are located on chromosome 3.  These loci were entered into TIGR and sequence  
of the genomic DNA of each gene, the coding region, and the amino acid make-up of the 
protein were retrieved.  The sequences from TIGR were blasted against sequences in the 
Saint Louis Bioinformatics Facility’s (SLBF) database of Cryptococcus neoformans 
genome information available at genome.slu.edu, to retrieve additional sequences 
necessary to generate the 1.2 kb flanks needed for homologous recombination to occur in 
Cryptococcus.  Freeware DNA alignment software, SerialCloner v.1-3 (available from 
http://serialbasics.free.fr/Serial_Cloner.html) was used to align the sequence of the gene 
(from TIGR) with the chromosomal sequence (from SLBF).  This allowed for the 
acquisition of the gene sequence and approximately 1.2 kb 5’ and 3’ flanks.  The process 
above was done for the following genes: AGO1, AGO2, DICER1, and DICER2. 
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Primer Design 
 Four sets of primers were designed for the AGO1 and AGO2 genes, as well as two 
sets of primers for the DICER1 and DICER2 genes.  Primer design was facilitated using 
Primer3 software available from the Massachusetts Institute of Technology at 
frodo.wi.mit.edu.   
Argonaute 1 Knockout Primers 
Primer sets were created to amplify three fragments- 1.2 kb regions of the 5’ and 
3’ flanks of the AGO1 gene, as well as a selectable marker.  The 5’ Out (IBO264) primer 
consisted of 25 nucleotides with a calculated melting temperature of 59.7°C; the 5’ In 
(IBO265) primer consisted of 23 nucleotides, and a calculated melting temperature of 
57.4°C.  A 3’ Out (IBO266) primer of 24 nucleotides was constructed as well, having a 
calculated melting temperature of 56.6°C.  The 3’ In (IBO267) had a calculated melting 
temperature of 59.5 and was made up of 21 bases.   These primers were complimentary to 
the template DNA.  
The overlap primers for AGO1 were designed to produce approximately 20 bases 
of overlap between the gene flanks and the selectable marker.  A Selection-3’ (IBO270) 
primer was constructed of 42 nucleotides, where 21 nucleotides were complimentary to 
the template DNA and the remaining 21 nucleotides were complimentary to the flanks of 
the neomycin (G418R), nourseothricin (NAT), and hygromycin (HYG) resistance 
markers.  The flanks of the plasmid cassettes for the selectable markers are identical, 
allowing for a single primer set to successfully amplify them.  A Selection-5’ (IBO504) 
primer was designed with 44 nucleotides.  Half of the nucleotides corresponded to the 5’ 
terminus of the selectable marker, and the other half corresponded to the 3’ terminus of 
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the 5’ flank, to generate the necessary overlapping region.  The 5’-Selection (IBO503) 
primer was also 44 nucleotides in length, with half of those nucleotides designed to add a 
5’flank overlap to the 3’ terminus of the selectable marker DNA for overlap generation.   
The 3’-Selection (IBO271) primer consisted of 42 nucleotides, half of which 
complimented the 5’ terminus of the 3’ gene flank, with the other half was 
complementary to the flanking regions of the three drug resistance markers listed above.  
All overlap-producing primers (IBO270, IBO271, IBO503, and IBO504) were PAGE 
purified to ensure primer integrity.  All eight AGO1 knockout primer sequences are 
shown in Table 2. 
Argonaute 2 Knockout Primers  
Primer sets were created to amplify the 5’ and 3’ flanks of AGO2 and selectable 
markers as with AGO1.  The 5’ OUT (IBO205) primer consisted of 21 nucleotides with a 
calculated melting temperature of 55.8°C; the 5’ IN (IBO206) primer consisted of 20 
nucleotides, with a calculated melting temperature of 50.0°C.  A 3’ OUT (IBO207) 
primer of 21 nucleotides was constructed to have a calculated melting temperature of 
63.2°C.  The 3’ IN (IBO208) had a calculated melting temperature of 59.5°C and was 
made up of 20 bases.   These primers were complimentary to the template DNA.  
The overlap primers for AGO2 were designed in the same manner as for AGO1.  
A Selection-3’ (IBO501) primer was constructed of 44 nucleotides, where 22 nucleotides 
were complimentary to the template DNA and the remaining 22 nucleotides wer 
complimentary to the flanks of the neomycin, noureseothricin, and hygromycin resistance 
markers.  A Selection-5’ (IBO210) primer was designed with 43 nucleotides.  Of those, 
36 matched the 3’ terminus of the 5’ flank; the remaining 6 nucleotides corresponded to 
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the 5’ terminus of the selectable marker.  The 5’-Selection (IBO209) primer was also 43 
nucleotides in length.  The 3’-Selection (IBO502) primer consisted of 42 nucleotides, half 
of which complimented the 5’ terminus of the 3’ gene flank, with the other half 
complementary to the flanking regions of the three drug resistance markers listed above.  
All overlap-producing primers (IBO501, IBO502, IBO209, and IBO210) were also 
PAGE purified.  All eight AGO2 knockout primer sequences are located in Table 3. 
Genomic DNA Extraction 
 Genomic DNA was extracted from overnight cultures of C. neoformans grown in 
liquid medium.  Prior to each genomic preparation, C. neoformans was inoculated into a 
5 mL liquid culture of yeast peptone dextrose (YPD) broth and grown in a G24 
Environmental Incubator/Shaker (New Brunswick Scientific Co., Edison, NJ) at 30°C 
with shaking for 16 hours.  After incubation, the cells were pelleted by centrifugation at 
13,000 rpm (17,900 x g) and resuspended in an extraction buffer made up of 50 mM Tris-
HCl, pH = 8.0, 20 mM EDTA, and 1% SDS.  Cells were lysed using a bead-beater 
(Biospec Products, Bartlesville, OK).  Breakage was optimized by drawing out 3-5 µL 
aliquots of cell suspension and viewing the cells under a LEICA DME light microscope 
(LEICA Microsystems, Buffalo, NY) at 1000X magnification.  Bead-beating was 
continued until 50-80% breakage was observed.  After beating, the cells were incubated 
at 70°C for ten minutes and then vortexed well.  200 µL of 5 M potassium acetate was 
added, as well as 150 µL of 5 M NaCl, and the cells were incubated on ice for twenty 
minutes.  Upon completion of the ice incubation, the cells were spun at top speed in a 
microfuge (14,000 rpm) for twenty minutes and the resulting supernatant was transferred 
to a clean microfuge tube.  450 µL of chloroform was added to the supernatant and this 
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solution was centrifuged for an additional ten minutes.  The aqueous phase was removed 
to a clean tube and 200 µL of 30% PEG-8000 was added.  The mixture was incubated on 
ice for ten minutes.  After the final incubation, the mixture was centrifuged for ten 
minutes at top speed in a micro-centrifuge and the supernatant was removed from the 
resulting pellet.  The pellet was resuspended in 50 µL of sterile water and placed at 4°C 
for short-term storage.  No genomic DNA preparations were quantified. 
Overlap PCR Protocol    
For OL-PCR, two separate rounds of PCR were performed.  The first round 
consisted of the PCR amplification of three separate fragments: the 5’ and 3’ 1.2 kb 
flanks of the genes to be deleted, as well as a selectable marker.  The selectable marker 
within the AGO1 deletion construct was a nourseothricin (NAT) resistance gene that was 
amplified from the GMC200 plasmid (a gift from Jenny Lodge).  The AGO2 deletion 
construct contained the hygromycin (HYG) resistance gene as the selectable marker 
which was amplified from the pTEL-HYG plasmid (a gift from Jenny Lodge).    
The first round of PCR was performed with TaKaRa Taq (TaKaRa Bio Inc., 
Kyoto, Japan).  The TaKaRa Taq polymerase has proofreading activity and does not add 
3’ adenine bases to the amplicons, as most non-proofreading Taq polymerases do.  The 
typical PCR reaction was run using the following master mix recipe: 1 µL (non-
quantified) template DNA, 1 µL each of the forward and reverse primer, 5 µL of TaKaRa 
10X PCR Buffer (100 mM Tris-HCl (pH=8.3), 500 mM KCl, 15 mM MgCl2, 10% 
glycerol), 1 µL 10 mM dNTPs, 0.5 µL TaKaRa Taq polymerase (equivalent of 2.5 
enzyme activity units), and 40.5 µL sterile water.  This 50 µL master mix was divided 
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into two 25 µL reactions; one contained a test, and the other served as a negative control.  
Primer concentrations used in the first round of PCRs are shown in Table 4. 
Conditions for the first round of PCR were as follows: an initial denaturation step 
of 30 seconds at 94°C, followed by 28 cycles of 94° for 30 seconds to denature the DNA 
strands, 58°C for 45 seconds to facilitate primer annealing, and 72°C for 5 minutes which 
allowed the polymerase to extend the primer, followed by a final extension step of 72°C 
for 10 minutes to complete any unfinished extensions.  PCRs were analyzed via agarose
gel electrophoresis to determine if the product had been obtained. 
The second PCR used the three fragments obtained from the first PCR as 
templates.  Before this PCR could be carried out, the initial PCR fragments (the 5’flank, 
the 3’ flank, and marker) were purified away from the primers and residual polymerase 
and buffer.  The QIAGEN QIAquick PCR column purification kit (QIAGEN Sciences, 
MD) was used to perform the necessary purifications.  The purified products were 
analyzed by DNA gel electrophoresis to determine the amount of each template to use in 
the second PCR.   
 The second PCR was performed using primers 2 and 7 (Figures 2a and 2b).  For 
this PCR, the AccuPrimeTM Pfx Polymerase (Invitrogen, Carlsbad, CA) was used.  The 
typical PCR reaction was run using the following master mix recipe: 1 µL of each of the 
three non-quantified template DNAs (the 5’ flank, the 3’ flank, and the marker), 1 µL 
each of the forward and reverse primer, 10 µL 10X AccuPrimeTM Buffer (200 mM Tris-
HCl (pH 8.4), 500 mM KCl, 15 mM MgCl2, 2 mM dGTP, 2 mM dATP, 2 mM dTTP, 2 
mM dCTP, thermostable AccuPrime™ protein, 10% glycerol), 0.5 µL AccuPrimeTM Pfx 
Polymerase (equivalent of 2.5 enzyme activity units), and 33.5 µL sterile water, divided 
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into two 25 µL reactions (one test and one negative control).  Where LongAmp Taq 
Polymerase was employed, the typical recipe was as follows: 1 µL of each non-quantified 
template DNA (the 5’ flank, the 3’ flank, and the marker), 1 µL each of the forward and 
reverse primer, 10 µL 5X LongAmp PCR Buffer (final reaction concentrations: 
60 mM Tris-SO4, 2 mM MgSO4, 3 % Glycerol, 0.06 % NP-40, 0.05 % Tween-20, 
20 mM ammonium sulfate, pH=9.0), 1 µL 10 mM dNTPs, 1 µL (equivalent of 2.5 
enzyme activity units) of LongAmp Taq Polymerase (New England BioLabs, Ipswich, 
MA), and 33 µL sterile water.  This 50 µL master mix was divided into two 25 µL 
reactions; one contained the necessary templates, and the other served as a negative 
control.  Also, to successfully amplify the nourseothricin marker, dimethylsulfoxide 
(DMSO) was added at a final concentration of 5% to reduce secondary structures and 
decrease the melting temperature of the G-C rich nourseothricin DNA fragment.  
Concentrations of the primers used in the second round (overlap) PCRs are displayed in 
Table 5. 
Conditions for the second round of PCRs were as follows: an initial denaturation 
step of 2:30 at 95°C, followed by 28 cycles of 95°C for 30 seconds to denature the DNA 
strands, 58°C (65°C for AGO2 primers IBO205 and IBO207) for 45 seconds to facilitate 
primer annealing, and 68°C for 7 minutes which allowed the polymerase to extend the 
primer, followed by a final extension step of 68°C for 15 minutes to complete any 
unfinished extensions. All OL-PCRs were done in a PTC-100 Thermal Controller (GMI 
Inc., Ramsey, MN). 
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Overlap PCR Optimization 
 To achieve proper amplification, reactions including DMSO, betaine, and bovine 
serum albumin (BSA) were attempted.  For PCRs containing betaine, the denaturation 
temperature was decreased to 93°C.  Also, to determine the proper annealing 
temperatures for the primers used, gradient PCR was performed using an Eppendorf 
MasterCycler Gradient Thermal Cylcer (Eppendorf North America, Westbury, NY).  The 
annealing temperature of 55°C was set with a gradient of ±10°C to determine the most 
efficient temperature for decreasing non-specific binding of the primers.  All OL-PCR 
products were gel purified using the QIAspin Gel Extraction Kit (QIAgen Sciences, MD) 
and stored at -20°C. 
Molecular Cloning Protocol 
Molecular cloning was first described by Chang et al. in 1973, and can be defined 
as the isolation of a DNA fragment which has been linked to an independently replicating 
plasmid (molecular vector) within a bacterial cell.  As the plasmid replicates, the DNA 
fragment which is inserted into that plasmid is also replicated by the bacterial host, thus 
creating cloned copies of the inserted DNA (Hershfield et al., 1974) 
The gene region with approximately 1 kb flanks was PCR amplified and cloned 
into a TA vector in order to create the complementation construct.  The typical master 
mix recipe for these PCRs was as follows: 1 µL template DNA (fresh, non-quantified 
cryptococcal genomic DNA), 1 µL each of the forward and reverse primer, 10 µL 5X
GoTaq PCR Buffer (proprietary make-up; pH=8.5, 7.5 mM MgCl2), 1 µL 10 mM dNTPs, 
0.5 µL GoTaq Polymerase (Promega, Madison, WI), and 35.5 µL sterile water.  The 
resulting 50 µL master mix was divided into two 25 µL reactions; one was a test, the 
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other, a negative control.  Parameters for these PCRs consisted of an initial denauratio  
step of 30 seconds at 94°C, followed by 28 cycles of 94° for 30 seconds to denature the 
DNA strands, 58°C for 45 seconds to facilitate primer annealing, and 72°C for 7 minutes 
which allowed the polymerase to extend the primer, followed by a final extension step of 
72°C for 15 minutes.  Amplicons were generated via GoTaq polymerase (Promega, 
Madison, WI) such that the PCR products would contain 3’-adenine nucleoside 
overhangs to allow for ligation of the PCR product into the TA vector that contains 
thymine overhangs. 
 Upon successful amplification of the genes, TA-cloning was performed as a 
means of inserting the gene into a vector that could be subjected to further molecular 
manipulations.  Two separate TA-cloning kits were used for this study; the pCR2.1 
TOPO Cloning Vector from Invitrogen (Carlsbad, CA) and the pDrive Vector from 
QIAgen (QIAgen Sciences, MD).  Both vectors contain multiple cloning sites within the 
LACZ gene, and a bacterial origin of replication so that the plasmid can be replicated, as 
well as kanamycin and ampicillin resistance genes.  Schematics of these vectors are 
illustrated in Figures 3 and 4, respectively.   
 Ligations were carried out per the manufacturer’s recommendations.  Insertio  
into the pDrive Vector were ligated by adding 1 µL of the 50 ng/µL vector, 5 µL of2X
Ligation Master Mix, 2 µL of fresh, non-quantified, column purified PCR product, and 
brought to a final volume of 10 µL with sterile water.  This ligation reaction was 
incubated at 16°C for 2.5 hours as the manufacturer recommended.  Insertions into the 
pCR2.1 TOPO vector were performed by adding 1µL of the 10 ng/µL TOPO Vector, 2 
µL of fresh, non-quantified un-purified PCR product, 1 µL of the supplied salt solution 
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(1.2 M NaCl and 0.06 M MgCl2), and brought to a final volume of 6 µL with sterile 
water.  These ligations were incubated at room temperature for 30 minutes. 
Bacterial Cell Transformation 
 Ligation reactions were transformed into chemically competent DH5α cells 
(Fisher Scientific, Pittsburgh, PA).  40 µL of cells were thawed on ice and 2 µL of the 
ligation was added.  The ligation/cell mixture was incubated on ice for 30 minutes.  Cells 
were then heat-shocked at 37°C for 45 seconds, and 300 µL of Luria Bertani (LB) broth 
was added.  The newly transformed cells were incubated at 37°C with shaking for one 
hour in a G24 Environmental Incubator/Shaker (New Brunswick Scientific Co., Edison, 
NJ) and then plated onto LB plates containing ampicillin (AMP) and X-gal.  Ampicillin 
killed the cells that did not receive the plasmid.  X-gal allowed for the screening of 
plasmids that had ligated without the incorporation of the PCR product because the LAC 
operon was functional in these bacteria, and the colonies appeared blue.  Colonies that 
had the insert appeared white and were harvested for colony PCR. 
Colony PCR Protocol 
 Colony PCR is a PCR-based technique that tests for the presence of an inserted
sequence from a plasmid without costly and time-consuming plasmid DNA preparations 
from numerous candidate bacterial colonies obtained from a single transformation.  
White colonies from the transformed ligations were selected and master plated on o an 
LB+AMP agar plate using a sterile toothpick.  The plate was incubated at 37°C for ~16 
hours to allow the cells to grow.  Immediately after streaking the colony onto the master 
plate, the toothpick was swirled in 5 µL sterile water that had been aliquoted into a 0.5 
mL PCR tube.  The DNA within the cells that were shed from the toothpick into the 
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water served as template for the reaction.  Taq polymerase, dNTPs, 5X GoTaq PCR 
Buffer, and primers (to amplify the inserted gene) were added in the proportions 
described above.  PCR was facilitated by an initial denaturing step of 2 minutes at 94°C 
(to break open the cells) and followed the standard PCR protocol described above.  
Products were analyzed via DNA gel electrophoresis for the presence of an amplicon.  
All colony PCR reactions were performed using an Eppendorf MasterCycler Personal 
(Eppendorf North America, Westbury, NY).  Primers used to amplify the different genes 
in colony PCR reactions are displayed in Table 6.  These primers were designed to 
amplify an approximate 600 bp section of the gene in order to perform PCR with minimal 
extension times.    
Plasmid Preparation 
 In samples where an amplicon was present, cells were harvested from the master 
plate and grown in LB+AMP liquid broth with shaking for ~16 hours prior to plasmid 
preparation.   After overnight growth, the bacterial cells were harvested from the 
LB+AMP broth by centrifugation and plasmid DNA was extracted from the cells using 
the QIAspin MiniPrep Kit (QIAgen Sciences, MD).  Plasmid DNA was eluted in 35 µL 
of sterile water and stored at 4°C.  To confirm the presence of an inserted DNA fragment, 
subsequent enzymatic plasmid digestions were performed.  The plasmid DNA was also 
diluted 1:10 with sterile water and used as a template for PCR as described above.   
Determining Restriction Sites for Plasmid Digestion 
 SerialCloner v. 1.3, a DNA alignment software available from 
http://serialbasics.free.fr/Serial_Cloner.html, was used in this study to etermine which 
enzymes could be employed to remove the open reading frame (ORF) of the inserted 
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genes (for knockout constructs), as well as which enzymes would cut only once and 
allow for the formation of the complementation constructs.  SerialCloner was also used as 
an in silica experimentation suite to perform PCR and restriction digests prior to running 
actual experiments in vitro.  Both the TOPO (Figure 3) and the pDrive (Figure 4) vectors 
contain a single EcoRI restriction site on each side of the insert.  Thus, plasmids thought 
to contain an insert were digested with EcoRI and the presence of an insert wa  
confirmed or rejected based on the banding pattern. 
Restriction Endonuclease Reactions 
 Vectors known to contain the inserted gene were linearized in order to create 
complementation constructs for the corresponding deletion constructs.  Pilot experiments 
were performed to confirm that the enzyme would indeed cut as it should given the 
correct conditions as supplied by the manufacturer (New England BioLabs, Ipswich, 
MA).  For these small-scale experiments, 3 µL of fresh prepared, non-quantified, TOPO-
AGO1 and pDrive-DICER2 plasmid DNA were digested separately by 1µL (equal to 100 
enzyme activity units) of the MfeI enzyme (New England BioLabs, Ipswich, MA), 1.5 
µL of the supplied 10X NEB 4 reaction buffer (50 mM potassium acetate, 20 mM Tris-
acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 7.9), 1.5 µL of 10X BSA 
(where required), and water was added to a final volume of 15 µl.  The digests were 
incubated in a 37°C water bath for approximately 2-3 hours to carry out the digestion.  
Upon completion of the incubation period, the digested plasmid was analyzed by DNA 
gel electrophoresis to determine if the digestion had proceeded as expected. 
 After pilot experiments confirmed the enzyme’s ability to produce the correct 
banding pattern, full digests were done as follows: 20 µL plasmid DNA, 3 µL of MfeI 
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(equal to 300 enzyme activity units), 6 µL supplied 10X NEB 4 reaction buffer, 6 µL 
10X BSA (where required), and water to a final volume of 60 µL.  Digests were 
incubated for four hours in a 37°C water bath.   
Plasmid Processing 
 Immediately following digestion of the plasmids, the digestion reactions were 
inactivated by heat incubation per the manufacturer’s instructions (where applicable).  If 
particular enzymes were not able to be heat inactivated, column purification was 
performed using the QIAquick Column PCR Purification kit (QIAgen Sciences, MD).  
Once the restriction enzymes had been inactivated or removed from the reaction, the ends 
of the DNA fragments were blunted by adding 1 µL, or 3 enzyme activity units, of T4 
DNA Polymerase (New England BioLabs, Ipswich, MA) and 3 µL of 2 mM dNTPs and 
incubating at 16°C in the MasterCycler Personal Thermal Cylcer (Eppendorf North 
America, Westbury, NY) for twenty minutes, followed by a step of 75°C for 10 minutes 
to heat-inactivate the polymerase.  After blunting, all vector fragments (i.e. not inserts) 
were treated with a calf intestinal alkaline phosphatase (CIP) to remove the 5’ p osphates 
from the vectors and prevent the vector from ligating to itself, decreasing back round.  
CIP treatment was performed by adding 1 µL (10 enzyme activity units) of CIP and 
incubating in a 37°C water bath for thirty minutes.  The vectors and inserts needed from 
the various digests were retrieved via gel purification with the QIAspin Gel Extraction 
Kit (QIAgen Sciences, MD). 
Ligation Protocol 
 For the complementations, a neomycin resistance gene was inserted into the 3’ 
flank of the gene such that when introduced, the complementation would re-introduce the 
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wild type gene (Figure 5).  Ligation reactions were setup using a TOPO+AG 1 plasmid 
that had been linearized with the MfeI restriction enzyme and the G418 selectable marker 
insert obtained from a HindIII digestion of the TDB546 plasmid.  Table 7 describes the 
typical makeup of a ligation reaction.  Reactions were facilitated by an overight, room 
temperature incubation period that allowed T4 DNA Ligase (New England BioLabs, 
Ipswich, MA) to join the insert and the vector, resulting in a complementation construct 
of AGO1.  Successful ligations were digested with restriction enzymes to determine the 
orientation of the insert within the plasmid.  Constructs were transformed into DH5α E. 
coli as described previously and frozen down to -80°C for long-term storage. 
Freezing Stocks of Plasmid-Containing Escherichia coli 
 Once cultures of E. coli cells were confirmed to contain any plasmid of interest 
(TOPO+AGO1, TOPO+AGO2, complemented genes, deleted genes, etc.) by colony PCR 
and plasmid digestion, cells were grown overnight in 5 mL of LB+AMP broth and 
prepared for storage at -80°C.  Tubes were clearly labeled with the strain name, the 
plasmid name, as well as the selectable markers contained in the plasmid, and this
information was also entered into a database shown in Table 9.  500 µL of fresh cell 
culture was mixed with 500 µL of 50% glycerol in sterile water.  The cells wre vortexed 
well and placed on dry ice briefly.   The cells were placed at -80°C in a Revco Ultima II 
Ultralow Freezer (Thermo Fisher Scientific, Waltham, MA) for long term storage of the 
cells containing the plasmid DNA. 
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RESULTS 
 
 
 
 The overall goal of this work was to create strains of Cryptococcus neoformans 
lacking the AGO1, AGO2, DICER1 and DICER2 genes; as well as to create 
complementation strains of these deletions.  Gene deletion was attempted emloying two 
methods: overlap PCR and molecular cloning.  Overlap PCR proved to be the more 
efficient of these two, allowing the creation of deletion constructs for both AGO1 and 
AGO2.  Molecular cloning was used, however, in an attempt to create complementation 
constructs for the AGO1 deletion.  The AGO2 deletion will be addressed later.  For 
unknown reasons, the DICER1 gene was not amplified via PCR.  Therefore, the DICER2 
gene was abandoned, and the focus shifted to the AGO1 and AGO2 genes. 
Overlap PCR  
Once sequence information is obtained, primers are designed to amplify the 5’ 
flank of the gene.  The forward primer consists of 20-25 complimentary bases to the 
5’terminus of the 5’ flank; however, the reverse primer is designed such that 20-25 bases 
match the template DNA and an additional 15-20 base portion which matches the 5’ 
terminus of the marker to be used to delete the gene.   
The marker region is amplified using a forward primer of approximately 40 bases, 
20 which match the marker and 20 which match the 3’ terminus of the 5’ flank.  The 
reverse primer used to amplify the marker contains 40 bases, 20 which match the marker 
and 20 which match the 5’ terminus of the 3’ flank.   
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The 3’ flank of the gene is amplified using a forward primer that contains a 
stretch of 20 nucleotides complimentary to the 3’ terminus of the marker, as well as 20 
nucleotides which compliment the 5’ terminus of the 3’ flank of the gene.  The reverse 
primer used to amplify the 3’ flank compliments the 3’ terminus of the 3’ flank (Figure 
2a). 
 The three separate amplicons achieved via the first round of PCR are then used in 
a second round.  Figure 2b illustrates the three fragments being fused by a PCR reaction 
using two inside primers.  The overlapping regions of the fragments allow the polymerase 
to amplify the 5’ flank, fusing it to the marker, and then fusing that piece to the 3’ flank,
creating a fusion product consisting of the gene flanks with a marker in the middle.   
 The three preliminary PCRs were obtained from fresh genomic DNA preparations 
of C. neoformans strain KN433α (serotype D) and purified using the QIAgen PCR 
purification kit columns (QIAgen Sciences, MD) (Figure 6a).  These amplicons were 
generated using the TaKaRa Taq Polymerase (TaKaRa BioSciences, Kyoto, Japan).  
Overlap PCR was attempted and the results showed slight amplification of some 
intermediate fragments, but not the entire overlap PCR we had hoped to generate (Figure 
6b).   
 To address the issue of template concentration, the OL-PCRs for the AGO1 and 
AGO2 deletion constructs were set up using various dilutions of template.  Each PCR was 
run with a 1:10 as well as a 1:20 dilution of the original genomic preparation (dilutions 
were created by addition of sterile water).  However, these PCRs gave no fragment of the 
expected size, and often showed the amplification of non-specific fragments.   
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The non-specific banding pattern could be the result of the annealing of primers to 
non-specific regions of the genome.  This can be addressed by varying the annealing 
temperature of the reaction to determine the best annealing temperature for a primer pair.  
Annealing temperature was optimized for the AGO2 amplicon.  Figure 7 clearly shows a 
decrease in non-specific banding as the annealing temperature is increased toward an 
optimum.  Using this technique, the optimal annealing temperature for primers IBO205 
and IBO207 amplifying the AGO2 gene was determined to be approximately 65°C.  
However, although this reduced the non-specific bands, the amplification of the specific 
overlap PCR fragment did not improve with annealing optimization.  
 Since template concentration changes and varying annealing temperatures of 
primers did not give the desired result, additional adjuncts that are known to improve 
PCR efficiency were tried in the overlap PCR procedure.  These adjuncts included the 
small molecules dimethyl sulfoxide (DMSO), dithiothreitol (DTT) and N,N,N-
trimethylglycine (betaine).  PCRs were first tested with a fin l concentration of 1.5 M 
betaine, but these reactions showed no improvement.  Betaine should decrease non-
specific binding and aid in DNA melting, allowing for more efficient amplification. 
However these data show that, for the primer pairs that were used, betaine actually 
inhibited PCR, even at the recommended concentration (data not shown).  Next, DMSO 
was added at a final concentration of 5%.  Like betaine, DMSO aids in DNA melting 
(especially those templates which have a high G-C content) while also decreasing 
secondary structure formation within single-stranded DNAs.  Following the work of 
Rasler et al. (2006), I also tried to use these adjuncts in combination to determine if that 
would allow specific fragments to be amplified with greater efficiency.  Overlap PCR 
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was repeated using the same amplicons shown in Figure 6a with the addition of a 
combinatorial enhancement solution (CES) (Rasler et al., 2006).  The CES was prepared 
as a 5X stock solution, and the recipe can be found in Appendix I.  Because of the betaine 
constituent of the CES, the denaturation temperature of the PCR was lowered to 93°C.  
This PCR showed some improvement over the original gel; however, the overlapping 
fragment was not achieved (data not shown).   
 Heat-stable DNA polymerases are an integral part of the PCR process.  These 
enzymes allow for the selection and addition of the complementary base to the growing 
strand of DNA during the PCR reaction.  However a plethora of heat-stable DNA 
polymerases are found in today’s market.  These enzymes fall within two major 
categories: non-proofreading and proofreading DNA polymerases.  The non-proofreading 
polymerases, although usually very robust, have less fidelity and are liable to make more 
mistakes while adding new bases (Ignatov and Kramarov, 2009), whereas the 
proofreading polymerases, although more accurate, are often less robust enzymes.  I used 
a number of these polymerases in order to determine which type of enzyme functions best 
for our purposes.  The non-proofreading polymerase GoTaq (Progmega, Madison, WI), 
and the proofreading polymerases TaKaRa Taq (TaKaRa Bio, Japan), and KTLA Taq 
(Wayne Barnes, Washington University) were not able to produce an overlap, although 
each one was capable of producing the preliminary PCRs and the entire gene regio .  
Since the proofreading polymerases are known to be less robust, cocktails of Taq 
polymerases were also formulated with the idea that if proofreading polymerases can 
initiate the production of the overlap PCR fragments, it might be possible for the more 
active non-proofreading enzymes to take over and increase the yield of the fragment.  In a 
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particular PCR, 0.25 µL (1.25 units of enzyme activity) of a robust non-proofreading Taq 
and 0.25 µL (1.25 units of enzyme activity) of a proofreading Taq were both added to the 
master mix, but this did not give the expected results.   
The overlap PCR was not obtained using any of the above parameters (data not 
shown).  Template concentration, primer annealing temperature, and the type of 
polymerase used were all systematically ruled out as being the reason for the failure of 
overlap fragment amplification.  I have also shown that, with the primer pairs in use, 
addition of various adjuncts did not improve the reaction result.  It was hypothesized that 
perhaps these amplicons were too cumbersome for the PCR protocol being used.  To test 
this, the entire gene regions of AGO1, AGO2, DICER1, and DICER2 were amplified 
using the outside primers for each (Tables 2 and 3).  The resulting bands are shown in 
Figure 8.  GoTaq polymerase (Promega, Madison, WI) successfully amplified AGO1, 
AGO2, and DICER2.  This showed that the length of the fragment being produced was 
not the limiting condition for the reaction. 
The results of a PCR using PAGE-purified primers to generate the preliminary 
PCRs are shown in Figure 9.  The resulting preliminary PCRs were used in an overlap
PCR.  The gel is shown in Figure 10.  To increase the yield of these PCRs, another Taq 
polymerase, AccuPrimeTM Pfx (Invitrogen, Carlsbad, CA), was acquired and used to 
generate the preliminary PCRs (Figure 11) and to perform an overlap PCR (Figure 12).  
The AGO1 deletion construct was successfully generated, as seen in Figure 12.   To show 
this, Figure 13 represents a schematic representation of the AGO1 OL-PCR product.  
AGO2, although present, showed a low yield.   To further increase the yield of an AGO2 
overlap deletion fragment, a few optimization experiments were conducted, inclu ing 
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adding betaine and DMSO separately, as well as increasing the annealing time from 30 
seconds to 45 seconds (data not shown).  Because no increase in yield was obtained, five 
individual PCRs were run without adjuncts (Figure 14).  These PCRs were pooled int 
one tube and the overlap fragment was gel purified (Figure 15).  A schematic 
representation of the AGO2 deletion construct is illustrated in Figure 16. 
Molecular Cloning 
 Concurrently with overlap PCR, molecular cloning techniques were engaged.    
The AGO1, AGO2, and DICER2 genes were successfully amplified via PCR (Figure 8).  
These amplicons were then successfully ligated into a vector.  Both the AGO1 and AGO2 
genes were successfully ligated into the pCR2.1 TOPO cloning vector from Invitrogen 
Inc. (Carlsbad, CA), while DICER2 was ligated into the pDrive vector from QIAgen 
Sciences (QIAgen Sciences, MD).  These ligations were tested via colony PCR and then 
confirmed through plasmid DNA preparation and digestion with EcoRI (New England 
Bio Labs, Ipswich, MA) (data not shown).  The TOPO cloning vector had greater ligation 
efficiency than the pDrive vector.  Of the 45 white colonies screened for a pDrive 
plasmid, only one showed an insert, the single pDrive-DICER2 plasmid.  The two TOPO-
AGO2 plasmids were identified after screening only 17 white colonies, and the lone 
TOPO-AGO1 plasmid was confirmed with only 16 white colony screenings.  However, 
for the purposes of this study, the pDrive-DICER2 plasmid was not investigated due to 
the co-required dicer gene (DICER1) which was unable to be amplified. 
 The linear plasmids are shown on an agarose gel in Figure 17.  The sequences of 
these plasmids were checked for possible restriction sites for the insertio  of he 
complementation marker.  The TOPO-AGO1 plasmid was found to have a single cut site 
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for the restriction enzyme MfeI (New England Biolabs, Ipswich, MA) which was located 
127 bases from the AGO1 gene stop codon. Ligating the linear TOPO-AGO1 plasmid 
(digested with MfeI) with the neomycin resistance marker (obtained from the TDB546 
plasmid via digestion with HindIII) created an AGO1 complementation construct (Figure 
18).  These constructs were tested by colony PCR and gave several results.  The first
eight colonies showed a positive, approximately 800 base pair band that lined up with the 
TDB546 positive control plasmid PCR (Figure 19).  However, there was also an 
unexpected band of approximately 2,000 base pairs with these PCRs (Figure 19). To 
address the unexpected 2,000 base pair band, a separate PCR was run using the TDB546 
neomcycin –containing plasmid and the IBB103 plasmid, which also contained the 
neomycin cassette (Figure 20).  The results from this PCR (Figure 20) were consistent 
with the results of the earlier PCR (Figure 19).  Descriptions of these colonies can be 
found in the complete database of frozen E. coli (Table 9).  
 Two of the eight colonies that contained the AGO1(Neomycin) plasmid were 
subjected to further testing in order to determine the orientation of the insert.  When
ligations are performed, the insert can orient in two separate ways.  The insert can be 
incorporated into the plasmid in the forward orientation (i.e., the same orientation it was 
within the source plasmid) or in the reverse orientation.  A schematic of the differences in 
orientation can be found in Figure 21. 
 The DNA shown in Figure 22 is the result of a EcoRI digestion of the 
AGO1(Neomycin)#1 and AGO1(Neomycin)#2 vectors.  The complementation construct 
AGO1(Neomycin)#1 was found to be in the correct forward orientation, whereas the 
complementation construct AGO1(Neomycin)#2 was found to be in the reverse 
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orientation.  Although this does not affect the validity of any complementation construct, 
it is an important quality control step, because knowing the composition of the nascent 
construct is of paramount importance.     
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Figure 1. The RNAi pathway.  dsRNA in the cytoplasm is digested into siRNAs by the 
Dicer protein.  The siRNAs are then unzipped and loaded into the RISC in an ATP-
dependent manner.  The RISC, armed with the ss-siRNA, finds the complimentary 
mRNA strand and binds it.  Upon binding with the mRNA, the Argonaute protein 
(rectangle) cleaves the mRNA at the 3’end, preventing translation into protein. 
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Figure 2a. Overlap PCR Amplification. The procedure is performed as follows: primers 
1 and 4 are used to amplify the 5’ flank of the gene; primers 8 and 5 are used to amplify 
the 3’ flank of the gene; primers 3 and 6 are used to amplify some marker.  The products 
of these PCRs are then used as templates in a reaction containing primers 2, and 7, which 
yield the final piece of DNA consisting of the 5’ flank fused to a selectable marker and 
the 3’ flank of the gene.  This figure was adapted from Davidson, et al., 2002. 
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Figure 2b. OL-PCR of three different PCR products.  Primers 2 and 7 amplify the 5’ 
flank, the marker, and the 3’ flank of the gene to be disrupted.  Here, the overlapping of 
the flanks and the marker allow for amplification throughout, resulting in one whole PCR 
product (deletion construct) containing the 5’ gene region and the 3’ gene region with a 
marker inserted where the mid-section of the gene would be.  
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Figure 3.  Graphic representation of the pCR2.1 TOPO vector from Invitrogen 
(Invitrogen, Carlsbad, CA).  This vector contains an associated topoisomerase and yields 
a high cloning efficiency of PCR products.  It contains ampicillin and kanamycin 
bacterial selection, a pUC origin, an f1 origin, and the multiple cloning site lies within the 
lacZα gene to allow for blue/white screening.  The plasmid also contains an M13 cloning 
site and a T7 promoter.  The figure above was downloaded from the Invitrogen website, 
www.invitrogen.com. 
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Figure 4. Graphic representation of the pDrive cloning vector from QIAgen (QIAgen 
Sciences, MD).  The vector contains both T7 and SP6 promoter which flank the cloning 
site.  The cloning site is located inside the lacZα gene to facilitate blue/white screening.  
This plasmid also contains both ampicillin and kanamycin bacterial selection, and 
possesses an f1 origin.  The figure above was downloaded from the QIAgen website, 
www.qiagen.com. 
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Figure 5. Creation of a complementation construct to re-introduce the wild type gene.  
The selectable marker is placed inside the 3’ flank approximately 300bp downstream of 
the stop codon, leaving the coding region of the gene intact while allowing for selection 
of colonies that received the resistance marker. 
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Figure 6a. Agarose gel of purified preliminary amplicons generated from C. neoformans 
genomic DNA that were used in an overlap PCR procedure.  Lane ‘L’ contains the DNA 
ladder labeled with appropriate base pair sizes.  Lanes 1-3 contain the 5’ flank, the G418 
marker, and the 3’ flank of the AGO1 gene, respectively.  Lanes 4-6 contain the 5’ flank, 
the G418 marker, and 3’ flank of the AGO2 gene, respectively.  
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Figure 6b.  Agarose gel of overlap PCR using the amplicons from Figure 6a with GoTaq 
polymerase.  The far left 1ane contains a DNA ladder labeled with the appropriate base 
pair sizes.  Lanes 1 and 2 are the test and negative control, respectively, for the AGO1 
overlap.  Lanes 3 and 4 are the test and negative control, respectively, for the AG02 
overlap.  No overlap was generated in these PCRs.  If the overlap had been generated, a 
band would be expected at approximately 5 kb for both AGO1 and AGO2. 
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Figure 7. Gradient PCR of the AGO2 overlap.  Annealing temperature was programmed 
for 54°C±10°C.  The two ‘L’ lanes contain a DNA ladder marked with the appropriate 
base pair sizes.  Each lane is labeled with a number 1-12. The numbers underneath the 
lane number designate the annealing temperature used in degrees Celsius.  All PCRs are 
the AGO2 OUT amplicon generated by primers IBO205 and IBO207 (Table 3) with the 
Go Taq polymerase.  Optimal annealing temperature for these primers is approximately 
65°C, as seen in lanes 9-12. 
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Figure 8. PCR of the entire AGO1, AGO2, DICER1 & DICER2 genes with approximately 
1Kb flanks.  The ‘L’ lane contains a 1Kb DNA ladder, and band sizes of the different 
amplicons match those expected (Table 1).  Lanes 1 and 2 represent the negative control and 
the AGO1 gene, respectively.  Lanes 3 and 4 represent the negative control and the AGO2 
gene, respectively.  Lanes 5 and 6 represent the negative control a d the DICER1 gene, 
respectively.  Lanes 7 and 8 represent the negative control and DICER2 genes, respectively. 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Preliminary PCRs for deletion constructs.  These amplicons were generated using 
PAGE-purified primers (Tables 1 and 2).  The left-most lane of each row, the ‘L’ lane, 
contains a marker labeled with the appropriate base pair sizes.  This gel shows a low yield of 
the 5’ flank of AGO1 (Lane 1), the 3’ flank of AGO1 (lane 2), and the NAT, HYG, and G418 
drug resistance markers containing overlapping regions to the AGO1 gene (lanes 3, 4, and 5).  
The bottom row consists of the same amplicons, except these pertain to AGO2. Lane 6 holds 
the 5’ flank.  Lane 7 holds the 3’ flank.  Lanes 8, 9, and 10 hold the NAT, HYG, and G418 
amplicons for AGO2. 
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Figure 10. Overlap PCR deletion constructs using fragments shown in Figure 9.  The ‘L’ lanes 
contain a DNA ladder marked with the appropriate base pair sizes.  This agarose gel depicts an 
amplicon consisting of the 5’ and 3’ flanks of the AGO1 gene with a nourseothricin selectable 
marker replacing the coding region of the gene in lane 1.  This amplicon is emphasized by the 
black oval.  The black rectangle shows the 5’ and 3’ flanks of the AGO1 gene with a hygromycin 
selectable marker replacing the coding region of the gene in lane 2.  The AGO1 + G418 overlap 
shows no result (lane 3).  The bottom row of this gel depicts the unsuccessful overlap PCRs of 
the AGO2 gene with the nourseothricin, hygromycin, and the G418 neomycin resistance markers 
(lanes 4-6).  Lanes 4 and 7 contain the negative control for these PCRs. 
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Figure 11. Preliminary PCRs for overlap performed with the AccuPrimeTM Pfx Taq 
Polymerase (Invitrogen Inc., Carlsbad, CA) and PAGE purified primers.  The ‘L’ lane 
contains a DNA marker labeled with the appropriate base pair sizes.  Lane 1 contains the 
negative control for the 5’ flank of AGO1 and lane 2 contains the test.  Lane 3 contains 
the negative control for the nourseothricin marker with AGO1 overlaps, and lane 4 shows 
the test.  Lane 5 contains the negative control of the 3’ flank of the AGO1 gene, whereas 
lane 6 shows the test.  Lane 7 was intentionally left blank.  The negative control for he 5’ 
flank of AGO2 is located in lane 8, with the test PCR being in lane 9.  Lane 10 contains 
the negative control for the hygromycin resistance gene with AGO2 overlaps, where lane 
11 contains the test PCR.  Lane 12 contains the negative PCR the 3’ flank o  AGO2, 
where lane 13 contains the test. 
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Figure 12. Overlap PCR of AGO1 and AGO2 with AccuPrimeTM Pfx.  The ‘L’ lane 
contains a DNA ladder labeled with the appropriate base pair sizes.  Lane 1 shows the 
negative control PCR of the AGO1+NAT OL-PCR shown in lane 2.  Lane 3 shows the 
negative control for the AGO2+HYG OL-PCR shown in lane 4. 
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Figure 13.  Graphic representation of the ∆ago1 gene deletion construct.  The construct 
consists of the 5’ flank of the AGO1 gene fused with the nourseothricin resistance marker 
and the 3’ flank of the AGO1 gene.  This schematic represents the synthesized DNA 
molecule found in Lane 3 of Figure 12. 
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Figure 14. Separate AGO2+HYG Overlap PCRs.  The ‘L’ lane contains a DNA ladder 
marked with the appropriate base pairs sizes.  Lanes 1-5 contain AGO2 overlap PCR 
products, which are emphasized by the black arrow, at approximately 5kb in size.  Thes 
amplicons were pooled together and gel purified.  Lane 6 shows the negative control for 
these PCRs. 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
                                                                            
Figure 15. Purified pooled AGO2+HYG OL-PCR.  The ‘L’ lane shows a DNA ladder 
marked with the appropriate sizes in base pairs.  Lane 1 contains the AGO2+HYG 
overlap PCR deletion construct and approximately 5kb in size.   
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Figure 16. Graphic representation of the ∆ago2 gene deletion construct.  The construct 
consists of the 5’ flank of the AGO2 gene fused with the hygromycin resistance marker 
and the 3’ flank of the AGO2 gene.  This schematic represents the syn 
thesized DNA molecule found in the right-most lane of Figure 14. 
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Figure 17. Linearized TOPO-AGO1 and the G418 resistance marker.  The ’L’ lane 
shows a DNA ladder marked with the appropriate band sizes.  TOPO-AGO1 was 
linearized with MfeI, and is shown in Lane 1.  The G418 marker was digested from the 
TDB546 plasmid using HindIII, and is shown in Lane 2. 
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Figure 18. TOPO-AGO1 Complementation Construct.  The above schematic represents 
the TOPO vector from Invitrogen (Carlsbad, CA.) containing the AGO1 
complementation.  A neomycin resistance marker was inserted into the 3’flank of the 
gene region. 
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Figure 19. AGO1 Complementation Construct Colony PCRs.  The left-most lane 
contains a DNA ladder marked with the appropriate base pair sizes.  Lanes 1-5 contain
neomycin marker bands at approximately 800 base pairs, and another unexplained band 
at approximately 2,000 base pairs for complementation samples 1-5.  Lanes 6-9 were 
intentionally left unloaded.  Lane L contains a duplicate of the DNA ladder.  Lanes 11-13 
contain an 800 base pair band as well as the unexplained 2000 base pair band for samples 
6-8.  Lane 14 contains the negative control for this PCR, and lane 15 contains a positive 
control PCR of the TDB546 plasmid. 
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Figure 20.  IBB103 Plasmid vs. TDB546 plasmid.  The left-most lane contains a DNA 
Ladder marked with the appropriate base pair sizes.  The second lane contains the 
IBB103 neomycin amplicon.  The third lane contains the TDB546 neomycin amplicon.  
The fourth lane contains the negative control PCR.  
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Figure 21.  Graphic representation of forward and reverse orientations.  The insert can 
orient into the 3’ flank of the gene in one of two ways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
 
 
 
 
 
 
Figure 22. Orientation of AGO1(Neomycin) #1 and #2 complementation constructs.  The 
Ladder lane contains the Invitrogen 1Kb Plus Ladder.  Lane 1 contains the uncut TOPO-
AGO1.  Lane 2 contains the AGO1(Neomycin) #1 plasmid cut with EcoR1 showing three 
bands, meaning the insert is in the forward orientation.  Lane 3 contains the 
AGO1(Neomycin) #2 plasmid also cut with EcoRI showing only two bands, meaning the 
insert is in the reverse orientation.  The fourth lane contains the TOPO-AGO1 plasmid cut 
with EcoRI, and the fifth lane shows the uncut TDB546 plasmid. 
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Figure 23. The RNAi Plasmid.  This plasmid contains two GAL7 promoters that 
transcribe the URA5 gene and a random piece of genomic DNA from both directions 
which produce dsRNA.  The GAL7 promoters are flanked by terminators (T).  This 
plasmid also contains a neomycin resistance marker for selection, and telomeres that 
stabilize the extrachromosomal DNA in Cryptococcus neoformans 
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Table 1. AGO1, AGO2, DICER1, DICER2 gene lengths and loci.  The table below 
describes the names, abbreviations, loci, and sizes of the four genes which were target for 
deletion in this study. 
Gene Name Gene Abbreviation Gene Locus Gene Size (bp) 
Argonaute 1 AGO1 CNJ00490 6080 
Argonaute 2 AGO2 CNJ00610 6130 
Dicer 1 NA CNC03670 5399 
Dicer 2 NA CNC03680 5080 
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Table 2. AGO1 knockout primers used for overlap PCR formation of deletion constructs of the 
Argonaute 1 gene. 
Description Name  Primer Sequence 
5' Out IBO264 5'-CAGGTAATGGCTCGAGCCTTCAAAG-3' 
5' In IBO265 5'-CTTGGGAGCCGTAGGTTTGATAC-3' 
3' Out IBO266 5'-GAGGCTACTACCGTTAAGAGGTTG-3' 
3' In IBO267 5'-CGCGCTATCTCGGAGGAGAAC-3' 
5' Selection IBO503 5'-CAGCCGCAACCCACAGTGAAATCCAGGAAACAGCTATGACCATG-3' Ŧ 
Selection 5' IBO504 5'-CATGGTCATAGCTGTTTCCGGATTTCACTGTGGGTTGCGGCTG-3' Ŧ 
3' Selection IBO271 5'-GAGGAGTCTACAGCCGAGTTCGTTGTAAAACGACGGCCAGTG-3' Ŧ 
Selection 3' IBO270  5'-CACTGGCCGTCGTTTTACAACGAACTCGGCTGTAG CTCCTC-3' Ŧ 
Ŧ denotes primers which were PAGE Purified 
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Table 3. AGO2 knockout primers used for overlap PCR formation of deletion constructs  
of the Argonaute 2 gene. 
Description Name Primer Sequence 
5' Out IBO205 5'-GATCGCCATGAGAAACCTGTC-3' 
5' In IBO206 5'-CGCAGGTAATACACTATCTG-3' 
3' Out IBO207 5'-CTTGGAGGTGGCAGGGCCAAG-3' 
3' In IBO208 5'-CTGCCTCCAAGTTCGCCGTC-3' 
5' Selection IBO209 5'-GAAGGAATCCTCTGTCGGCAAGCAGGAAACAGCTATGACCATG-3' Ŧ 
Selection 5' IBO210 5'-CATGGTCATAGCTGTTTCCTGCTTGCCGACAGAGGATTCCTTC-3' Ŧ
3' Selection IBO502 5'-CTGGAACAGCGACGTATGTGACGGTTGTAAAACGACGGCCAGTG-3' Ŧ 
Selection 3' IBO501 5'-CACTGGCCGTCGTTTTACAACCATCACATACGTCGCTGTTCACG-3' Ŧ
Ŧ denotes primers which were PAGE Purified 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
Table 4. Primer Concentrations used in the first round of all OL-
PCRs 
 
Gene Primer Name Primer Alias Stock Concentration 
Reaction 
Concentration 
AGO1 IBO264 5' Out 32.5 µM 0.65 µM 
AGO1 IBO266 3' Out 35.8 µM 0.716 µM 
AGO1 IBO270 Selection 3' 50 µM 1 µM 
AGO1 IBO271 3' Selection 50 µM 1 µM 
AGO1 IBO503 5' Selection 50 µM 1 µM 
AGO1 IBO504 Selection 5' 50 µM 1 µM 
AGO2 IBO205 5' Out 30.5 µM 0.61 µM 
AGO2 IBO207 3' Out 22 µM 0.44 µM 
AGO2 IBO501 Selection 3' 50 µM 1 µM 
AGO2 IBO502 3' Selection 50 µM 1 µM 
AGO2 IBO209 5' Selection 50 µM 1 µM 
AGO2 IBO210 Selection 5' 50 µM 1 µM 
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Table 5. Primer Concentrations used in the second (overlap) round of all OL-PCRs 
Gene Primer Name Primer Alias Stock Concentration Reaction Concentratio  
AGO1 IBO265 5' In 40.1 µM 0.80 µM 
AGO1 IBO267 3' In 32.9 µM 0.65 µM 
AGO2 IBO206 5' In 24.5 µM 0.49 µM 
AGO2 IBO208 3' In 33.3 µM 0.66 µM 
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Table 6. Primer sequences used in colony PCR. 
Description Name Sequence 
AGO1 Forward Primer IBO272 5'-CTCCGATTCACCAAAGCCGGC -3' 
AGO1 Reverse Primer IBO273 5'-CGTCTCGGAAGAACAAGATGC-3' 
AGO2 Forward Primer IBO213 5’-GGACGCTGCTAAGCTTCTC-3’ 
AGO2 Reverse Primer IBO214 5’-GTAGGGGGTTTAGCAGCTTCC-3’ 
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Table 7. Representation of a typical ligation reaction.  Each ligation consisted of a 
control ligation containing only the vector, and two test groups with increasing amounts 
of insert incubated with the ligation.  Reactions were incubated at room temperature for 
16 hours. 
  Vector Only Reaction A Reaction B 
Vector 2 µL 2 µL 2 µL 
Insert - 3 µL 6 µL 
10X T4 DNA Ligase Buffer 2 µL 2 µL 2 µL 
T4 DNA Ligase- 2000 Units 1 µL 1 µL 1 µL 
Sterile Water 15 µL 12 µL 9 µL 
Total 20µL 20µL 20µL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Primers used for confirming G418 Complementation Constructs.  The table 
below gives the sequences for the G418 Sense and Antisense primers used in this 
study to detect complementation in a colony PCR technique. 
Description Name Sequence 
G418 Forward Primer g418-s 5'-GATCCATGATTGAACAATAT-3' 
G418 Reverse Primer g418-as 5'-TTGGACCAGATGTACCCCGCG-3' 
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Table 9. Complete database of frozen E. coli containing plasmids.  The table describes 
the strain name, the plasmid contained in the strain, the selectable markers that can be 
used, the original bacterial strain type, and the date frozen. 
Strain 
Name Plasmid 
Selectable 
Marker Bacterial Strain 
ACB001 pCR2.1-AGO1 (#1) AMP, KAN  NEB DH5α 
ACB002 pCR2.1-AGO1 (#2) AMP, KAN  NEB DH5α 
ACB003 pCR2.1-AGO1 (#3) AMP, KAN  NEB DH5α 
ACB004 pCR2.1-AGO1 (#4) AMP, KAN  NEB DH5α 
ACB005 pCR2.1-AGO1 (#5) AMP, KAN  NEB DH5α 
ACB006 pCR2.1-AGO1 (#6) AMP, KAN  NEB DH5α 
ACB007 pCR2.1-AGO1 (#7) AMP, KAN  NEB DH5α 
ACB008 pCR2.1-AGO1 (#8) AMP, KAN  NEB DH5α 
ACB009 pCR2.1-AGO1 (#9) AMP, KAN  NEB DH5α 
ACB010 pCR2.1-AGO1 (#10) AMP, KAN  NEB DH5α 
ACB011 pCR2.1-AGO1 (#11) AMP, KAN  NEB DH5α 
ACB012 pCR2.1-AGO1 (#12) AMP, KAN  NEB DH5α 
ACB013 pCR2.1-AGO1 (#13) AMP, KAN  NEB DH5α 
ACB014 pCR2.1-AGO1 (#14) AMP, KAN  NEB DH5α 
ACB015 pCR2.1-AGO1 (#15) AMP, KAN  NEB DH5α 
ACB016 pCR2.1-AGO1 (#16) AMP, KAN  NEB DH5α 
ACB017 pCR2.1-DICER2 (#17) AMP, KAN  NEB DH5α 
ACB018 pDrive-Dicer2 (#26) AMP, KAN Invitrogen OneShot 
ACB019 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB020 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB021 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB022 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB023 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB024 pDrive-Dicer2 (MP14) AMP, KAN Invitrogen OneShot 
ACB025 pCR2.1-AGO1 (#13) AMP, KAN NEB DH5α 
ACB026 pCR2.1-AGO1 (IB#2) AMP, KAN NEB DH5α 
ACB027 pCR2.1-AGO1 (IB#3) AMP, KAN NEB DH5α 
ACB028 pCR2.1-AGO2 (#14) AMP, KAN NEB DH5α 
ACB029 pCR2.1-AGO2 (#16) AMP, KAN NEB DH5α 
ACB030 pCR2.1-AGO1(Neo)#1 AMP, KAN NEB DH5α 
ACB031 pCR2.1-AGO1(Neo)#2 AMP, KAN  NEB DH5α 
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DISCUSSION 
 
 
 
 Cryptococcus neoformans is the causative agent of cryptococcosis in 
immunocompromised patients (Buchannan & Murphy, 1998).  Treatments for this 
disease are generally not effective and no advancements in antifungal therapies have been 
made in over a decade (Odds, Brown, & Gow, 2003).  The purpose of this study was to 
create deletion strains of C. neoformans that lacked the AGO1, AGO2, DICER1, and 
DICER2 genes- four of the genes that are believed to play a role in the RNAi biochemical 
pathway.  Because PCRs of only the AGO1, AGO2, and DICER2 genes were successful 
(Figure 8), the study was continued using only the AGO1 and AGO2 genes.  Since 
DICER1 did not successfully amplify by PCR, deleting DICER2 by itself would not 
necessarily change the RNAi phenotype.  Redundancy in the functions of the two DICER
genes may lead to residual RNAi activity remaining in the ∆dicer2 strains.  Deletion 
constructs for both the AGO1and AGO2 genes were successfully created using the 
overlap PCR method described previously (AGO1 Figure 13; AGO2 Figure 16).  
However, these PCRs required much optimization for many reasons.   
 Many things can cause a PCR to fail.  Some conditions that may lead to the 
production of unwanted amplicons include high concentrations of template DNA, high 
concentrations of oligonucleotides, and the annealing temperature used in a given 
reaction.  It has been found that template concentration can have a major impact on PCR
performance (Renshaw-Gegg and Guiltinan, 1996).  An excess amount of genomic DNA 
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of high molecular weight can often lead to inefficient amplification of PCR fragments.  
Annealing temperatures, if not optimized, can generate non-specific amplification due to 
non-specific binding of the primers, i.e., the primers are capable of partially binding to 
multiple regions within the template, thus amplifying unwanted portions of that templat .  
Changing the template and primer concentration, as well as performing gradient PCR 
allowed for both the amplification of the preliminary PCRs (Figure 6a).  The sam
optimization allowed the amplification of three of the four gene regions in their entirety 
(Figure 8).  Because of this, the conclusion was made that amplicon size was not an issue 
for the DNA polymerases being used.  DNA polymerases may also have an impact upon 
PCR efficiency.  In this study, several different Taq polymerases were usd.  The best 
result was obtained with the Pfx Accuprime Taq Polymerase, a proofreading polymerase 
marketed by Invitrogen (Carlsbad, CA). 
The overlapping regions generated by the primers are of paramount importance to 
the overlap PCR procedure.  Although Davidson and his colleagues (Davidson et al., 
2002) had used desalted but unpurified primers for generating overlap PCR fragments, it 
appears that purified primers may yield better results in certain cases.  In order to increase 
the integrity of the overlapping regions of the three amplicons (which is generat d by the 
primers), primers were PAGE-purified.    PAGE-purified primers allow fr any 
incompletely synthesized primers to be removed from the stock, thus leaving only the 
complete, full primer.  Interestingly, no OL-PCR using non-purified primers gave any 
overlap result, although PAGE-purification is not generally necessary for OL-PCR 
(Davidson et al., 2002).  The caveat to this is that I did not use the non-purified primers 
with the Pfx Accuprime Taq polymerase in a PCR. 
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The initial attempt at an overlap PCR with the purified primers yielded very little 
DNA (Figure 10).  To correct this, an alternative Taq polymerase was used that generated 
a much higher yield of the three preliminary PCRs, and ultimately, a greater quantity 
overlap band for the AGO1 deletion construct.  The AGO2 deletion construct, however, 
was always seen at a lower yield than the AGO1, and betaine seemed to inhibit the PCR.  
Rather than wasting many expensive reagents in an attempt to optimize the quantity of 
the AGO2 deletion construct, another approach was taken.  Five individual PCRs were 
run (Figure 14) and the overlap products (the AGO2 deletion constructs) from each PCR 
were pooled together and purified in order to generate enough DNA for an attempt at 
biolistics (Figure 15).  The AGO2 deletion construct was not used as a template for PCR 
to increase DNA for two main reasons.  The first reason concerned the integrity of the 
primer binding sites for the PCR, and the other concerned the overall integrity of the 
sequence of the amplicon.  Any mistake made by the polymerase could have led to 
potential inactivity of the selectable marker.  This is not a concern for the original AGO2 
deletion construct, but copying a copy could lead to the buildup of  erroneous bases in the 
DNA amplicon. 
Because deletion constructs were successfully created for both the AGO1 and 
AGO2 genes, complementation constructs were attempted as well.  Complementation is  
necessary step in any gene deletion study.  Deletion constructs allow for the creation of 
deletion strains leading to the study of the function of any given gene.  However, 
complementation constructs can be used to rescue a deletion strain by reintroducig the 
wild type gene, therefore confirming that the results gleaned from studies of the deletion 
strain are directly related to the deletion of the target gene and not related to some other 
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phenomenon or some step in the deletion process (an artifact of the transformation and 
deletion protocol).   
Construction of the complementation vector for the AGO1 deletion was 
successfully completed using traditional molecular cloning methods that allowed the 
insertion of a neomycin marker into the TOPO-AGO1 cassette.  Because there was an 
unexpected band in these PCRs (Figure 20), another PCR was run to address the issue 
(Figure 21).  The IBB103 plasmid that also contains the neomycin resistance marker gave 
the same banding pattern as the TDB546 plasmid using the primers located in Table 8.  
Because these two separate plasmids gave the same result using exact PCR conditions, it 
was concluded that the eight colonies screened as potential AGO1 complementation 
constructs do contain the neomycin resistance marker in the correct location.  Figure 22 
shows the orientation of the AGO1 complementation plasmids of the AGO1(Neomycin) 
#1 and #2 plasmids, confirming that AGO1(Neomycin) #1 plasmid contains the insert in 
the forward orientation and that AGO1(Neomycin) #2 contains the insert in the reverse 
orientation.  For our purposes, restriction enzyme digests proved more simple and more 
high-throughput than sequencing, as these plasmids are over 10 kb, a size that is not ideal 
for DNA sequencing reactions.  These nascent plasmids are available for 
complementation of the deletion strains of C. neoformans upon their creation.   
Complementation of AGO2 was not possible during the scope of this study 
because the TOPO-AGO2 plasmid does not contain a single restriction enzyme site near 
the stop codon, making it impossible to add a complementation marker into the plasmid.  
Another methodology to perform this task is proposed in the Future Work section.   
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 Deletion constructs of both the AGO1 and AGO2 genes were submitted for 
biolistics at the Doering Lab at Washington University in St. Louis, MO.  However there 
is no estimated time for the biolistics to be completed.  This issue will be further 
discussed in the Future Work section. 
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FUTURE WORK 
 
 
 
Transformation of Cryptococcus via Biolistics to Produce Deletion Strains 
 As the deletion constructs are already prepared, the next step in this project would 
be to transform C. neoformans cells with these constructs to make the corresponding 
deletion strains.  Crptococcus neoformans can be transformed by two processes: 
electroporation or biolistics.  However, biolistics is the preferred choice if ntegration of 
the DNA constructs is required.  Incorporation of transformed sequences into the genome 
occurs at a very low frequency by the process of electroporation.  Recent work has shown 
that the addition of telomeric sequences to the plasmid increases transformation 
efficiency by electroporation by orders of magnitude (Indrani Bose, personal 
communication 2009) but that these plasmids mostly remain extrachromosomal.  The 
overlap PCRs can be used directly in the biolistics process because, for reasons that 
remain unclear, C. neoformans, preferentially accepts linear DNA over circular plasmid 
DNA (Toffaletti and Perfect, 1993, Davidson et al., 2000). 
The deletion constructs (generated by OL-PCR) will be transformed into the 
KN433 MAT α and KN433 MAT a-Serotype D strains of Cryptococcus neoformans 
(Nielsen & Heitman, 2005).  KN433 MAT α will be transformed with the ago1::NAT 
construct, while the ago2::HYG constructs will be transformed into the KN433 MAT a 
strain.  Transformed cells will be grown on plates with the appropriate drug 
(nourseothricin for ago1 and hygromycin for ago2) in an incubator at 30°C for 3-5 days 
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for growth of individual fungal colonies (adapted from Toffaletti and Perfect, 1993).  Due 
to equipment and spatial limitations, all biolistics will need to be performed at the 
Doering Lab, 10-230 McDonnell Pediatrics Building, Washington University Medical 
Campus, St. Louis, MO., 63130.   
Creating AGO1 and AGO2 Double Deletions 
 KN433 MAT α and KN433 MAT a are congenic strains of Cryptococcus 
neoformans, differing only from one another at the MAT locus, allowing them to mate.  
Therefore other than the MAT locus, they should differ only in the particular argonaute 
gene deletion.   
Double deletions can be obtained by mating the ago1::NAT KN433 MAT α and 
the ago2::HYG KN433 MAT a strains on V8 agar as previously described (Nielsen & 
Heitman, 2005).   The F1 progeny can then be grown on selectable YPD+NAT+HYG 
agar by incubating in an incubator at 30°C for 3-5 days for fungal growth.  The surviving 
colonies would be tested for the presence of the correct deletion (as described below).   
Screening Transformants for Gene Deletion 
All the surviving colonies from the above transformations that are nourseothricin 
and hygromycin resistant could be selected for genomic preparation.  Colonies would be 
grown overnight in 5 mL of YPD broth.   Genomic preparations of fresh cultures would 
be performed as previously described (in the Methods and Materials Section).  The 
genomic DNA then can be used as a template in PCR reactions to amplify the NAT 
marker (for the ∆ago1 strains) and the HYG marker (for the ∆ago2 strains), and these 
PCRs need to be analyzed by DNA gel electrophoresis.  The colonies with the correct
PCR results will have to be checked by Southern hybridization for insertion of the 
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construct in a single locus of the genome replacing the wild type gene of choice alone.  
This is because Cryptococcus cells often incorporate exogenous DNA at several places in 
their genome. 
Creation of an AGO2 Complementation Construct 
 
 Because the TOPO-AGO2 plasmid lacks a single restriction enzyme site within 
300 base pairs from the stop codon (which is the distance arbitrarily taken to be necessary 
for termination of transcription), molecular cloning techniques used for the AGO1 
complementation will not suffice.  To generate an AGO2 complementation, a PCR-based 
strategy will need to be employed to amplify the entire AGO2 gene with 1 kb 5’ 
untranslated region (UTR) and 3’ UTR.  A selectable marker (such as the neomycin 
resistance gene) can also be amplified and biolistically co-transformed with the AGO2 
gene fragment.  This kind of co-transformation strategy has been previously used to 
obtain transformants in C. neoformans (Goins, Gerik, and Lodge, 2006).  After 
transformation, cells will be screened for the presence of the neomycin resistance gene 
(by plating on YPD+G418 plates) and the absence of the hygromycin resistance gene.  In 
addition, the colonies with the right combinations of markers should also be tested by 
PCR to ensure the AGO2 ORF is in the correct context (i.e., to ensure that the AGO2 gene 
was inserted in place of the HYG marker, in the correct chromosome).  Because the G418 
PCR was co-transformed, it is not necessarily associated with the gene, and could have 
been inserted someplace else, possibly disrupting other genes.  To correct this, the AGO2 
(G418) MAT-α strain will need to be mated with a wild type MAT-a strain.  The F1 spores 
can then be tested for the presence of G418 via PCR.  After the G418 has been removed 
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from the genome, the ∆ago2 will have successfully been complemented with the wild 
type gene. 
Testing for the Presence of RNAi 
The transformed Cryptococcus will then be tested for the ability to perform 
RNAi.  To do this, the RNAi plasmid IBB103 (Figure 23) will be transformed into the 
∆ago1, ∆ago2, and ∆ago1∆ago2 mutant strains of C. neoformans.  This plasmid contains 
a neomycin resistance marker and an RNAi cassette that allows for the production of 
dsRNA corresponding to the sequence of the URA5 gene fragment cloned in between two 
GAL7 promoters in opposite directions (Figure 24).  If RNAi is functioning properly, the 
presence of the dsRNA from the URA5 gene fragment in the plasmid would lead to 
silencing of the URA5 gene and no uracil production.  This would make the strain a ura5 
mutant without any change occurring to the genomic DNA.  However, if RNAi has been 
disrupted, the URA5 gene would not be silenced, completing uracil biosynthesis.   
Deletion strains will be plated on minimal media that contains neomycin, uracil, 
galactose and 5-fluoro-orotic acid (5FOA).  If cells did not receive the plasmid, they will 
be unable to grow due to the presence of neomycin in the media.  Only cells that received 
the plasmid will be able to grow.  The galactose in the media will activate the GAL7 
promoters and the URA5 dsRNA will be expressed.  Without RNAi, the protein encoded 
by URA5 will use the 5FOA as a substrate, resulting in 5-fluoro-uracil, a toxic pyr midine 
killing the cells.  Alternatively, if RNAi is functioning, cells will grow because RNAi 
will silence the URA5 gene and the cells will use the uracil provided in the media. 
To test the complementation constructs, a variant of the RNAi plasmid will be 
used that contains a hygromycin resistance marker in lieu of the neomycin marker, as 
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neomycin was used to create the complementations.  Deletion strains will be plated on 
minimal media that contains hygromycin, uracil, galactose and 5FOA.  The test for these 
complementation constructs should be carried out in the same manner as the neomycin 
deletion tests (discussed above). 
Other Studies Involving ∆ago1 and ∆ago2 Mutants  
 Further studies would be performed to classify the status of known factors of 
virulence in C. neoformans such as the formation of the polysaccharide capsule, 
thermotolerance and mannitol synthesis.  Also, these mutants, if incapable of RNAi, 
would be used in an end-tail murine virulence study to determine if the absence of RNAi 
abrogates virulence in these fungi. 
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Appendix I 
 
 
 
PCR Reagents 
 
Sterile Water- Sterile water was prepared by obtaining mmH2O using an ELGA Classic 
Ultrapure Water Purification System (High Wycombe, UK) and autoclaving the water at 
15 psi and 121°C for 30 minutes under slow exhaust of a STERIS Remaunfactured 3021 
Gravity Steam Sterilizer (Life Sciences Group, Mentor, OH).    
 
5X CES Stock- A 1 mL, 5X stock of the combinatorial enhancement solution for overlap 
PCR was prepared by combining 540 µL of a 5M betaine stock, 6.7 µL of  1M 
dithiothreitol (DTT), 67 µL of DMSO, and 55 µL of a 1µg/mL BSA stock with 331.3 µL 
of sterile mmH2O.   The stock solution was aliquoted into four aliquots and stored at        
-20°C. 
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Appendix II 
 
 
 
Antibiotic Stock Solution Preparation 
  
1000X Ampicillin Stock- ampicillin stocks were created by adding 500 mg of ampicillin 
sodium salt (ACROS Organics, Morris Plains, NJ) to 10 ml of mmH2O.  The solution 
was filter sterilized using a 10 ml sterile syringe and a FisherBrand 0.22 µm sterile fil r 
(Fisher Scientific, Pittsburg, PA) This 1000X ampicillin stock was divided into ten 1 ml 
aliquots and stored frozen at -20°C. 
 
1000X Kanamycin Stock- kanamycin stocks were created by adding 500 mg of 
kanamycin monosulfate (Fisher Scientific, Pittsburg, PA) to 10 ml of mmH2O and filter 
sterilized using a 10 ml sterile syringe and a FisherBrand 0.22 µm sterile filter (Fisher 
Scientific, Pittsburg, PA)  This 1000X kanamycin stock was divided into ten 1 ml 
aliquots and stored at -20°C. 
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Appendix III 
 
 
 
Preparation of Electrophoresis Buffers and Agarose 
 
Tris-Borate-EDTA (TBE) Buffer- A 10X stock solution of TBE buffer was prepared by 
dissolving 108g of Tris base and 55g of Boric Acid in 200 µL of a 0.5M EDTA solution 
and enough diH2O to bring the final volume to 1 L.  To dilute this solution for use as an 
electrophoresis running buffer, 100 mL of the stock was diluted using 900 mL of 
mmH2O.   
 
Loading Dye- A 6X loading dye was prepared using 10mM Tris HCl (pH=7.5) + 1mM 
0.5M EDTA in 50% glycerol.  To this solution, a few grains of bromophenol blue were 
added.  The loading dye was stored in 1 mL aliquots at -20°C.   
 
Agarose Gel- Agarose solution was prepared in bulk and stored in a bottle on the 
benchtop until needed as follows: 3 grams of Electrophoresis Grade Agarose (Fisher 
Scientific, Pittsburg, PA) was added to 300 ml of a 1X TBE Buffer solution.  The 
solution was microwaved until the agarose was completely dissolved.  The agarose 
solution was allowed to cool to 60°C and 15 µL of ethidium bromide was added.  When 
needed, this “stock” solution was melted in the microwave and poured into the 
appropriate gel casting tray. 
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Appendix IV 
 
 
Bacterial Growth Media Preparation 
 
Luria-Bertani Media Plates + Antibiotic- These media plates were produced by 
dissolving 25 g of LB Broth (ACROS Organics, Morris Plains, NJ)  and 15 g of 
BactoTMAgar (Becton-Dickson Inc., Franklin Lakes, NJ) in 1 L of mmH2O.  The media 
was autoclaved at 15 psi and 121°C for 30 minutes under slow exhaust of a STERIS 
Remaunfactured 3021 Gravity Steam Sterilizer (Life Sciences Group, Mentor, OH).  
Sterile media was slowly stirred and allowed to cool to approximately 37°C, and 1 ml of 
the appropriate 1000X antibiotic stock was added.  The media was stirred for an 
additional minute, and 15 mL plates were poured from the media.  Plates were allowed to 
solidify and excess condensation dried out before being moved to 4°C for storage. 
 
Luria-Bertani Liquid Broth- Luria-Bertani broth was prepared by dissolving 25 g of 
LB Broth (ACROS Organics, Morris Plains, NJ)  in 1 L of mmH2O and autoclaving for 
30 minutes at 121°C under 15 psi pressure in a STERIS Remaunfactured 3021 Gravity 
Steam Sterilizer (Life Sciences Group, Mentor, OH).  Sterile LB Broth was stored at 
room temperature. 
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Appendix V 
 
 
Yeast Growth Media Preparation 
 
Yeast-Peptone Dextrose (YPD) Media Plates- YPD media plates were prepared by 
dissolving 50 g of YPD Broth (Sigma-Aldrich, Inc., St. Louis, MO) and 15 g of 
BactoTMAgar (Becton-Dickson Inc., Franklin Lakes, NJ) in 1 L of mmH2O.  The media 
was autoclaved at 15 psi and 121°C for 30 minutes under slow exhaust of a STERIS 
Remaunfactured 3021 Gravity Steam Sterilizer (Life Sciences Group, Mentor, OH).  15 
mL Petri plates were poured from this media.  Plates were allowed to solidify an  dry 
before they were placed at 4°C for storage. 
 
Yeast-Peptone Dextrose (YPD) Broth- YPD broth was prepared by dissolving 50 g of 
YPD Broth (Sigma-Aldrich, Inc., St. Louis, MO) in 1 L of mmH2O.  Prior to sterilization, 
the media was divided into 10 100 mL aliquots.  These aliquots were autoclaved at 15 psi 
and 121°C for 30 minutes under slow exhaust of a STERIS Remaunfactured 3021 
Gravity Steam Sterilizer (Life Sciences Group, Mentor, OH).  Sterile LB media was 
stored at room temperature.   
 
 
